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Alcoholic liver disease (ALD) is a potentially fatal complication of heavy drinking, yet only a minority of heavy drinkers develop ALD. This variable susceptibility has been thought to be genetic in origin, but of the many candidate genes suggested, based on association studies, virtually none have been independently confirmed. 
Our hypothesis is that genetic predisposition to ALD is modest and that environmental cofactors (as early as during intrauterine life) play an important role in predisposing heavy drinkers to ALD. The aims of this research are: (a) to evaluate familial predisposition to ALD, (b) to assess the association of decompensated ALD (D-ALD) with several, previously poorly characterised potential environmental factors using a case-control strategy, (c) to identify (“capture”) every case of D-ALD in Sheffield over a defined time period, through detailed analysis of overlapping electronic databases and thus assess prevalence, incidence, demographics and geographical distribution.
 Case-Control Study: We recruited two cohorts of heavy drinkers (> 60 units/week (male) and 40 units/week (female)) in Sheffield between 1998 and 2010. Cases had D-ALD (Child’s grade B or C) while controls had no evidence of serious liver disease. Data were collected regarding: 1) drinking behaviour and presence of liver disease in relatives, 2) lifetime alcohol intake, total and individual beverages, 3) cigarette consumption and 4) early life events, including prematurity and birthweight (maternal recall, validated by available records). Family history results show ALD and liver disease relative risk in relatives of cases vs controls to be 1.1 to 1.3, suggesting that familial predisposition to ALD is modest. There were no significant differences between the two cohorts in regard to birthweight, prematurity, mothers’ smoking in pregnancy or subjects’ current or past smoking. Lifetime cigarette consumption was negatively associated with risk of ALD.

























Alcohol is a chemical which is consumed socially by millions of people around the world. Its concentration varies from one beverage to another, and the amount we drink is best expressed in grams of pure alcohol and units. One unit of pure alcohol is equal to about 8 gm in 10 ml and is the amount contained in half a pint (285 ml) of average-strength beer, a 125 ml glass of wine, a small (50 ml) glass of sherry and a single (25 ml) measure of spirits [1].

1.1	The Physiology of Alcohol

The main form of alcohol we drink is ethyl alcohol or ethanol, produced via two processes – fermentation and distillation. It is a small water-soluble molecule which, when ingested, is slowly absorbed from the stomach but more rapidly from the small bowel before being distributed freely throughout the body. Blood alcohol concentration varies according to factors including volume, concentration (10–20% solutions are the most rapidly absorbed) and the nature of the alcoholic drink, the presence or absence of food in the stomach and the rate of gastric emptying. Over 90% of absorbed alcohol is metabolised in the liver, with the reminder excreted unchanged in the urine, sweat and breath [2].
Oxidation of ethanol is mediated by three major hepatic enzyme systems: alcohol dehydrogenase (ADH) in the cytoplasm, the microsomal ethanol oxidising system in the smooth endoplasmic reticulum of mitochondria (predominantly CYP2E1) and catalase in the peroxisomal membrane. All these biochemical pathways produce acetaldehyde as their toxic by-product [3], which is later oxidised by acetaldehyde dehydrogenase (ALDH) into acetate. 
1.2. Alcohol-induced Liver Disease 

Alcoholic liver disease (ALD) is the result of the direct toxic effect of alcohol and its metabolites on the liver’s hepatocytes. It is considered to be a spectrum of morphological changes from fatty liver to hepatic inflammation and necrosis (alcoholic hepatitis – AH) to progressive fibrosis (alcoholic cirrhosis)  ADDIN EN.CITE [4-6]. Clinically, it also has a broad spectrum of manifestation, ranging from minimal symptoms to fulminant liver injury characterised by ascites, encephalopathy or coagulopathy. Progression of alcohol-induced liver injury is not orderly. Alcoholic hepatitis is often found superimposed on established cirrhosis and may have coexistence of all the above features. 
Simple fatty liver or steatosis is the earliest and most common feature of ethanol metabolism and is due mainly to an increased synthesis and decreased degradation of fatty acids. Healthy volunteers given non-intoxication doses of alcohol for a period of 2–4 days developed fatty liver [7]. A degree of fibrosis (perivenular fibrosis) can be present at the fatty liver stage and indicates a high risk of progression to cirrhosis [8]. 
Alcoholic hepatitis is a syndrome of progressive inflammatory liver injury associated with long-term heavy intake of ethanol. Upon microscopic examination, the liver exhibits characteristic features like centrilobular ballooning, necrosis of hepatocytes, neutrophilic infiltration, megamitochondria, Mallory hyaline inclusions and fibrosis (perivenular and pericellular), in addition to fatty liver and cirrhosis [4].
Cirrhosis is defined as a diffuse process of fibrosis and conversion of normal liver architecture into structurally abnormal nodules [9]. This process is considered irreversible and carries a 5–10% risk of hepatocellular carcinoma [10].
1.3	Pathogenesis of ALD 

Oxidative stress
A number of mechanisms have been implicated in the pathogenesis of ALD. A significant part of the abnormality in hepatic structure and function is through the toxic effect of acetaldehyde through binding to hepatic protein, free radical formation and lipid peroxidation  ADDIN EN.CITE [11, 12]. The liver detoxifies acetaldehyde to acetate but a significant amount accumulates during metabolism, and to an even greater degree in alcoholics [13]. When ethanol is oxidised to acetaldehyde, nicotinamide adenine dinucleotide (NAD) is converted to the reduced form of NADH. This, in turn, shuttles into the mitochondria where huge amounts of highly reactive oxygen species (ROS) are generated, leading to cell damage and necrosis. The shift (NAD → NADH) is thought to impair carbohydrate and lipid metabolism and cause impairment of gluconeogenesis and the diversion of metabolism to ketogenesis and fatty acid synthesis. Also, the NADH-induced inhibition of the mitochondrial β-oxidation leads to accumulation of intracellular lipids, thus promoting steatosis [14] [15].

Metabolism-associated transcription factors
Alcohol induces lipogenesis and inhibits fatty acid oxidation through regulation of lipid metabolism-associated transcription factors. Acetaldehyde can lead to inactivation of the peroxisome proliferator-activated receptor (PPAR)-α, a nuclear hormone receptor that controls transcription of a range of genes involved in free fatty acid transport and oxidation [16], leading to inhibition of fatty acid oxidation in the hepatocyte.

In addition, alcohol causes upregulation of sterol regulatory element-binding protein 1c (SREBP-1c), a transcription factor that promotes fatty acid synthesis via upregulation of lipogenic genes. This is done directly through acetaldehyde  ADDIN EN.CITE [17] or indirectly through activating factors such as the endoplasmic reticulum response to cell stress  ADDIN EN.CITE [18], adenosine  ADDIN EN.CITE [19], endocannabinoids  ADDIN EN.CITE [20] and (​javascript:void(0);​) LPS signalling via Toll-like receptors (TLRs)  ADDIN EN.CITE [21]. Disruption of SREBP-1c in mice reduced ethanol-induced fatty liver, indicating its role in ALD. 

Immunologic Mechanisms
A significant amount of evidence for the role of the immune system in ALD pathogenesis comes from studies of dramatic activation of the cytokine cascade. Alcohol intake increases the intestinal permeability to a variety of substances like dietary, bacterial and other antigens. Most important are bacterial endotoxins, such as lipopolysaccharides. Gut permeability and circulating LPS levels are increased in humans with alcoholic liver injury [22]. LPS sensitise Kupffer cells through the CD14 receptor and cause exaggerated transcription of pro-inflammatory cytokines [23] [24]. These include interleukin 1 and 6 (IL-1 and IL-6) which are mainly involved in the synthesis of acute-phase proteins and interleukin 8 (IL-8) associated with neutrophil activation. Infiltration of the liver by neutrophils is a prominent feature of alcoholic hepatitis and is also related to upregulation of a number of chemokines and cytokines (e.g. TNF-α, IL-17)  ADDIN EN.CITE [25]. Tumour necrosis factor α (TNF-α) is thought to be a mediator of liver cell necrosis in animal models [26] and its levels correlated with hepatocyte injury in subjects with alcoholic hepatitis [27]. Transforming growth factor beta (TGF-β) may be critically involved in fibrogenesis through the activation of hepatic stellate cells and formation of fibroblasts, fibrosis and, ultimately, cirrhosis.

Ethanol also inhibits natural killer cells, which when activated inhibit liver fibrosis by producing interferon (IFN)-γ  ADDIN EN.CITE [28].  
It is also believed that acetate, which results from acetaldehyde breakdown and has no direct hepatotoxicity, can regulate inflammatory response in patients with AH via the upregulation of pro-inflammatory cytokines in macrophages  ADDIN EN.CITE [29].
 
Energy Metabolism
The rate of ATP synthesis in liver cells exposed to ethanol is typically reduced. Chronic alcohol consumption depresses the activity of all mitochondrial complexes, with the exception of complex II, leading to several abnormalities in the mitochondrial respiratory chain. As a result, the energy metabolism of liver cells can be severely impaired, leading to tissue damage and apoptosis [30].

Fat metabolism enzymes 
AMPK inhibits fatty acid synthesis and promotes fatty acid oxidation via the inactivation of ACC enzyme activity. Alcohol consumption inhibits AMPK activity in the liver, leading to decreased phosphorylation and increased activity of ACC and decreased activity of carnitine palmitoyltransferase 1; each has an important role in the development of alcoholic fatty liver  ADDIN EN.CITE [31].      

1.4	The relationship between cumulative alcohol dose and liver disease

There is no completely safe level of alcohol. Epidemiologic surveys have demonstrated a correlation between decreased cirrhosis mortality and a decrease in the availability of alcohol during both World War One and Prohibition in the USA [32]. This risk later increased, with the accumulated alcohol intake suggesting a dose–response relationship between alcohol ingestion and alcohol-induced liver damage  ADDIN EN.CITE [33, 34]. The risk showed significant increase above 7–13 drinks/week for women and 14–27 drinks/week for men [35]. However, increasing intake above this level may not be associated with further increase in the risk of ALD or in the severity of liver injury [36] [37].   

On the other hand, drinking in low amounts at regular intervals can cause health benefits by lowering the risk of coronary heart disease (CHD) and ischaemic stroke to a greater degree than for both abstainers and heavier drinkers, after adjustment for other established risk factors. This cardio-protective effect applies across age ranges but is seen mainly over the age of 40, where the incidence of CHD is highest. The level of risk reduction may be as much as 25% when consuming an average of 20–30 g per day compared to non-drinkers [38], although the optimal level is likely to vary by individual and across populations [39].


1.5 Alcohol consumption in the United Kingdom and related mortality

1.5.1 Alcohol consumption trends

In the UK there has been a steady rise in alcohol consumption in the last half of the twentieth century. The per capita consumption of alcohol for adults (aged 15 and older) has nearly doubled from less than 6 litres/year in the early 1960s to over 11.5 litres /year in 2004  . (Table1 and Figure1). 
However these figures are still considered underestimates as they do not take into account unrecorded alcohol consumed. This includes alcohol produced privately, smuggled alcohol, or ones obtained from another country so recorded outside it. The World Health Organisation (WHO) estimates UK unrecorded alcohol consumption to be approximately 1.7 litres per adult in 2004 and 1.2 litre in 2010 

Interestingly and from 2005 onwards there has been a downward trend in the amount of alcohol consumed with figures around 10 L/year in 2011 .This coincided with a fall  of household spending on food and drink in real terms by 3.1% and eating out expenditure by 5.6%.  Purchases made when dining out accounted for 23% of total alcohol intake in 2012. Alcohol consumption while dining out were 22% lower in 2012 than in 2009 showing a significant downward trend (2012 Living Costs and Food Survey (LCFS) by Office of National Statistics (ONS))

Type of alcohol and gender differences
Previously the increase in consumption in the UK has been overwhelmingly driven by wine the consumption of which increased with age [40]  , yet recent years have seen wine overtaken by beer at 37 % , wine 34 % , spirits 22% and other beverages at 7% . A more detailed look at this showed normal strength beer is predominant among men and wine among women (Drinking: Adults' behaviour and knowledge, 2009 Omnibus Survey)

This was further illustrated in data from the ONS in the Drinking Habits Amongst Adults report 2012 [41] .In this survey the respondents were asked questions about their alcohol consumption in the week prior to the interview. The types of drink most consumed in that week varied with age and sex. The majority of men had drunk normal strength beer, lager, cider or shandy (62%); a third had drunk wine (33%), and just over a fifth had drunk spirits (22%). In contrast, the majority of women had drunk wine (64%); a quarter had drunk spirits (26%), and a fifth (19%) had drunk normal strength beer, lager, cider or shandy

Drinking patterns 
Earlier data showed that In the UK 10% of the population are tea totals, 80% drink within the recommended alcohol level of 21 units/week for men and 14 units /week for women  and about 10% exceed this limit. (Government figures 2003). Of the later group about 80 % drink up to 50/30 (M/F) units/week and 20% exceeds this limit. There is however within these groups an overlap of individuals who drink heavily on single occasions or who “binge” drink (i.e drink more than eight units of alcohol in one day for a men and six for a women )  [42]. 




























































The ONS report in 2012 quoted above also included data on drinking patterns. When the respondents were asked questions about alcohol drinking the week prior to the interview, one in five adults did not consume alcohol at all. Also there was a decrease in the number of frequent drinkers in the UK in recent years yet the percentage of excess drinking was still raised among adults who had drunk alcohol in the last week. Just over half of men and women drank more than the recommended daily amounts, including 31% of men and 24% of women who drank more than twice the recommended amounts. Young people (those aged 16 to 24) were more likely to have drunk very heavily at least once during the previous week (27%).Only 3% of those aged 65 and over were very heavy drinkers. 

As with the fall in total alcohol consumption and frequent drinkers, another report showed a there has been a slight downward trend in binge drinking levels in England over the last four years; from 2007 highs of 25% and 16%, the percentage of both male and female consumers who binge drink has fallen to 19% and 12% in 2010, respectively (Statistics on Alcohol, England 2010)




















1.5.2 Alcohol-related liver disease

As a consequence of the increased alcohol intake , Alcohol-related morbidity and mortality is a major health concern in the UK [45]. The Global Burden of Disease Study (supported by the World Health Organization and World Bank) showed that among established market economies, in the UK, alcohol accounted for 10.3% of disability adjusted life years (DALYs) compared with 11.7% for tobacco and 2.3% for illicit drugs [46].
Excessive consumption (​http:​/​​/​www.netdoctor.co.uk​/​alcoholanddrugs​/​alcohol_toomuch.htm​) of alcohol is the most common cause of cirrhosis. Another cause is chronic viral hepatitis, especially hepatitis C. Alcohol consumption will increase the rate of progression of cirrhosis in subjects with hepatitis B infection [47], hepatitis C infection [48] and haemochromatosis [49].









Figure 3: Time trends in age-standardised mortality rates for liver cirrhosis per 100,000 by    




Analysis of the last 30 years of the twentieth century showed a manyfold increase in the number of deaths from liver cirrhosis among both men and women of all age groups.
In 1970, England and Wales had a much lower death rate for liver cirrhosis – about seven times lower – than the European Union average. Over the following 30 years the death rate attributable to liver cirrhosis in England and Wales rose in comparison to that of our European Union neighbours, where the figures began to fall. Most EU countries are showing declining trends in deaths from liver cirrhosis, although levels are generally still higher than the current rate for England and Wales (Figure 3).
Signs of this major upturn in the incidence of chronic liver disease and cirrhosis are also reflected in hospital admissions statistics, where numbers doubled between 1970 and the mid-1980s and have continued to steadily rise. By 1999, there were about 9,000 admissions with a main diagnosis of ALD and about 3,000 admissions with cirrhosis of the liver. 
The most recent figures derived from the Health and Social Care Survey using hospital coding data show that about one million admissions (broadly) related to alcohol were recorded in 2012/13, of which 50,500 were ALD (ICD-10 code 70) [52].   












Figure 4: Alcohol-related death rates per 100,000 in the UK, 2002–2012 (ONS)

This increase in mortality may be partly explained by longer-term trends in alcohol consumption but also potentially by changing patterns of consumption. Cirrhosis takes time to develop, with alcohol damage to the liver building up over many years until such time as the liver begins to malfunction or fail. This is why the trend is so worrying. It suggests that patterns of increased drinking starting at earlier ages are beginning to have serious public health implications.

In addition to these alarming figures, the 2013 report by the National Confidential Enquiry into Patient Outcome and Death found that care given to hospital patients with liver disease was less than good in more than half of cases [53]. This led to a comprehensive commission review and recommendations for reducing mortality and improving care for these patients in the UK  ADDIN EN.CITE [54].


1.6  Prognosis and Recovery 
Once alcoholic hepatitis and cirrhosis develop, continuing alcohol consumption is a major predictor of poor prognosis. In clinically compensated alcoholic cirrhosis, the five-year survival rate is about 90% in persistent abstainers, falling to below 70% in persistent drinkers. Once decompensated liver disease develops, the five-year survival rate falls to 30% in patients who continue drinking [55]  ADDIN EN.CITE [56]. 

The liver can regenerate after injury or loss of tissue and it is noted that some patients with alcoholic hepatitis are able to achieve spontaneous resolution of liver function abnormality. Yet there are no studies into the effect of alcohol on hepatocyte proliferation in patients nor into the effect of decreasing alcohol intake as opposed to complete abstinence.
In recent work we documented the frequency and determinants of liver function recovery (defined by Alb > 35grm/L and bilirubin < 34mmol/L ) following hospital discharge [57]. I analysed the results of 197 patients admitted to the RHH with D-ALD between 1998 and 2005, 117 (59%) of which recovered. Drinking behaviour after discharge was classified as: 1: completely abstinent, 2: reduction to below safe limits, 3: reduction but above safe limits and 4: no reduction of prior heavy intake (Figures 4, 5).
More than half of the patients in this cohort showed recovery of liver function over two years. Recovery was highly predictive of survival and was more likely in patients who either abstained or reduced their alcohol intake, in younger patients and in those with less severe liver dysfunction. Even in patients who fail to reduce their drinking, recovery may still occur, suggesting that D-ALD is partly influenced by factors other than alcohol intake. 

Figure 5:  Recovery by subsequent drinking behaviour







1.7  Risk Factors for Alcoholic Liver Disease

Only a minority of heavy drinkers develop ALD; in fact, the majority of long-term heavy drinkers develop fatty liver. The Dionysos study, a large cohort study of prevalence of ALD in two northern Italian communities suggested that drinking > 30 gram of ethanol/day increased the risk of developing ALD; however, even with a daily consumption of > 120 gm/day the risk of liver disease was only 13.5% and that of cirrhosis was 6% [58]. 
This suggests that other factors, either genetic or environmental, play a role in understanding the basis for this variable susceptibility and this has implications for the treatment and prevention of ALD.   

1.7.1 Genetic factors   

(1)	Genes
ALD is a complex disease and for years the interplay of genes was thought to be an important factor in predisposition. A large twin study reported differences in concordance rates of ALD between mono and dizygotic twins (14.6% and 5.4% respectively) [59]. 
There is evidence to support a genetic element to alcoholism which can in turn affect ALD with combined analyses of twin studies showing that the overall heritability for alcoholism is approximately 50% [60]. It is also known that heavy drinking (HD) has a familial component and a well-documented hereditary nature [61]. 
Putative mechanisms of ALD include oxidative stress, pro-inflammatory cytokines, ischaemia and immune-mediated damage [62], in addition to alcohol, iron and collagen metabolism. Genetics of ALD might be explained by the potentially significant polymorphism of genes relating to these mechanisms.
A number of studies describing associations between ALD and several of these genes have been published over the last 15 years (reviewed by Bataller) [63]. These studies have varied in size and quality and most reported associations have either not been confirmed or have been actively refuted by other studies. Indeed, only one association has been independently confirmed – that of a polymorphism in the gene for the anti-inflammatory cytokine interleukin-10 [64] [65].
Interestingly, recent whole-genome analysis of a number of liver diseases such as NAFLD have identified PNPLA3 as a new candidate gene. This was later confirmed as a risk factor for cirrhosis and ALD [66], a finding since replicated in three further case-control studies  ADDIN EN.CITE [67]. 
In addition, familial predisposition to a disease is suggestive of genetic predisposition. I explore this characteristic of ALD in more detail in Chapter 4. 
 
(2) Gender
Although the majority of patients with ALD are male, females appear to be more susceptible to the toxic effects of alcohol as they have a significantly higher risk of developing cirrhosis at a lower level of alcohol intake, true for any given level of alcohol intake [68] [35]. However, our unit showed no male-female differences whether or not there was ALD, and it is possible that there is no difference in susceptibility at higher levels of alcohol intake, i.e. > 100 u/week (see Chapter 6).  
 There are a number of possible explanations for any difference. The first is the gender difference in ethanol pharmacokinetics. Women appear to have higher peak blood alcohol levels than men after an equal dose of alcohol  ADDIN EN.CITE [69, 70.331]. This may be due to a smaller volume distribution due to lower total body water content because of a lower weight and higher proportion of fat mass, or possibly due to lower gastric ADH activity [71]. Diminished activity accounts for reduced first-pass metabolism in women and is very low in alcoholic women, therefore allowing more ethanol to reach the liver. However, significant gender differences in gastric ADH activity were not confirmed in other studies. Gastric ADH activity is modulated by other factors such as genetics, age, drugs and gastric morphology. Namely, gastric ADH decreases with age so that this gender difference is found only in younger people [72]. Finally, gastric metabolism of ethanol is quantitatively much lower than that of the liver.
Another theory is related to oestrogen, which may contribute to ethanol-induced liver injury by increasing gut permeability and portal endotoxin levels and increased expression of cytokines from Kupffer cells.
(3) Ethnic differences
Ethnicity also plays a role in variable susceptibility to ALD. In the United States, cirrhosis rates are higher in black men than in whites, while Hispanics present the highest cirrhosis mortality. Collateral analyses of other causes of death do not support alternate explanations of these findings as artefacts of demographic misclassification [73]. Hispanic and black active drinkers are more likely to have a twofold increase in liver enzymes when compared to whites [74]. 




(1)	Birthweight and prematurity 
Birthweight has direct links with the gestational age (​http:​/​​/​en.wikipedia.org​/​wiki​/​Gestational_age" \o "Gestational age​) at which the child was born and can be estimated during pregnancy (​http:​/​​/​en.wikipedia.org​/​wiki​/​Pregnancy" \o "Pregnancy​) by measuring fundal height (​http:​/​​/​en.wikipedia.org​/​wiki​/​Fundal_height" \o "Fundal height​). Birthweight can be classified into: 
1-	Large for gestational age: Weight is above the 90th percentile at gestational age.
2-	Macrosomia: Weight is above a defined limit at any gestational age.
3-	Appropriate for gestational age: Normal birthweight.
4-	Small for gestational age: Weight is below the 10th percentile at gestational age.
5-	Low birthweight: Weight is below a defined limit at any gestational age; low birthweight infants are those born weighing less than 2,500 g, with very low birthweight referring to infants with a birthweight < 1,500 g.
Prematurity has recently increased in the UK; researchers found that in 2006, 78 out of every 1,000 babies were born weighing less than (2.5 kg), amounting to a total of more than 50,000 babies. In 1989, the figure was 67 out of every 1,000 babies born underweight.
The ‘foetal origins hypothesis’, or programming, suggests that adverse influences during intrauterine life can lead to permanent alterations in foetal structure and physiology which predispose to adult disease. Such factors include maternal and foetal nutrition, genetic metabolic and endocrine factors. The hypothesis is strongly supported by experimental studies on animals. Recent studies suggest that a wide range of outcomes are associated with decreased size at birth, which can be a result of growth retardation in term babies or prematurity. Numerous studies have attempted, with varying degrees of success, to show links between birthweight and conditions in later life. I explore these links in more detail in Chapter 5. Also, there are no studies into such links to ALD, which I study and present in the same chapter. 

(2) Smoking  
Cigarette smoking causes many life-threatening diseases, including lung cancer, colon cancer, emphysema and heart disease. Each year more than 400,000 Americans die from causes related to the smoking of cigarettes. One in every five deaths in the United States is smoking related. Estimates show that about one-third of all adults smoke. Adult men seem to be smoking less, but women and teenagers of both sexes seem to be smoking more. Smoking affects the entire body, including the digestive system (reference).
There are a number of studies into the impact of smoking on autoimmune disorders and the liver, although the evidence is somewhat conflicting. I will allude to this in further detail in Chapter 5.

(3) Alcoholic beverages and drinking pattern 
Total lifetime alcohol was considered a factor in cirrhosis risk [78], however data from our case-control cohorts do not support this and it is likely to be a threshold effect, as I will demonstrate in my analysis in Chapter 6. The Dionysus study suggested that drinking multiple different alcoholic beverages increases the risk of developing ALD  ADDIN EN.CITE [58]. Data from our unit showed that patients consumed more spirits than controls, although not by a statistically significant amount. Other studies have confirmed that the risk of ALD is not related to the usual choice of alcoholic beverage (wine, beer or hard liquor)  ADDIN EN.CITE [33, 79, 80]. Steady daily drinking may carry a higher risk than binge drinking [80]. ALD patients presenting to our unit had an average of 30 years’ drinking and had not had a preceding binge [81].

(4) Nutrition
Ethanol metabolism yields about 7 kcal/g of energy on complete oxidation to carbon dioxide and water. Alcoholic beverages have little nutritional value aside from calories and are less adequate as a source of energy than carbohydrates.
Ethanol given to rats in the 1940s resulted in the development of fatty liver, something which was prevented when their basal diet was supplemented with choline [82]. This led to the hypothesis that alcohol is not a direct liver toxin and to the rise of the ‘malnutrition’ theory as a cause of alcohol-induced liver disease. However, this theory was challenged by the fact that it was not reproduced in humans and that starvation per se does not cause cirrhosis. Later, the direct hepatotoxic effects of alcohol were shown histologically in alcoholic and non-alcoholic volunteers regardless of dietary variation [7] and alcohol caused fibrosis and cirrhosis in  well-fed baboon models [83]. 
 
Observations of increased incidence of cirrhosis in malnourished populations, a common finding of malnutrition in alcoholics, and the experimental production of fatty liver and cirrhosis through certain deficient diets has led to ongoing debate that deficiencies of certain nutrients and vitamins may be a factor contributing to the development of liver disease in the chronic alcoholic.  
However, these associations do not necessarily implicate malnutrition as the cause of liver disease, but rather expose it as a result. In addition, changes observed in animals may not be the same as those that occur in humans. In general, malnutrition can be caused by decreased dietary intake, malabsorption and alterations in the metabolism of nutrients, decreased storage and increased losses.  

A.	Methionine folate metabolism  
There is increasing evidence of the role played by altered methionine folate metabolism in the development of ALD. Glutathione is a scavenger of free radicals and is decreased in rats by alcohol ingestion, while cysteine, a constituent of glutathione, has been shown to render acetaldehyde non-toxic. S-adenosyl-L-methionine (SAM) is a key metabolite that regulates hepatocyte growth, death and differentiation. Animal and human studies suggest a link between ethanol consumption and hepatic SAM depletion. Chronic ethanol administration depleted the hepatic concentrations of SAM and was associated with liver injury of variable magnitude from fatty liver in rats [84]; fatty liver, inflammation and fibrosis in baboons [85]; fatty liver and inflammation in micropigs  ADDIN EN.CITE [86]; and hepatitis in humans [87].
SAM supplementation may attenuate ALD by decreasing oxidative stress through the upregulation of glutathione synthesis [88], reducing inflammation via the down-regulation of tumour necrosis factor- [89] and the upregulation of anti-inflammatory interleukin-10 (IL-10) synthesis  ADDIN EN.CITE [90], inhibiting the apoptosis of normal hepatocytes and stimulating apoptosis of liver cancer cells  ADDIN EN.CITE [91]. However, clinical trials on SAM as a potential treatment have not been conclusive and a Cochrane review showed no survival benefit [92].
Folate is a water-soluble vitamin that plays an integral role in methionine metabolism and DNA synthesis and helps maintain normal concentrations of homocysteine, methionine and SAM. Studies have reported decreased serum or red blood cell folate concentrations in the majority of chronic alcoholic patients who consume > 80 g ethanol/d [93]. More than 40 years ago, a US study reported a greater incidence of very low serum folate concentrations (< 3.0 ng/mL) in patients with ALD than in alcoholics without liver disease [94].  
Folate deficiency alone does not lead to liver injury, but it can accentuate or promote the development of ALD. Studies using the folate-deficient, ethanol-fed micropig model  ADDIN EN.CITE [86] have shown that the onset of ALD is mediated by the effect of ethanol on methionine metabolism, which is amplified by folate deficiency. Possible mechanisms in the subsequent study of liver samples of the same animals include increasing hepatic homocysteine concentrations (which has been linked to ALD) [95] [96], decreasing hepatic SAM and glutathione concentrations, increasing cytochrome P4502E1 activation and lipid peroxidation and upregulating endoplasmic reticulum stress markers. 
Betaine (trimethylglycine) is an important human nutrient obtained from a variety of foods, and is also available as a dietary supplement. It provides a methyl group to homocysteine to form methionine. This helps to maintain an adequate supply of liver methionine for the synthesis of SAM and regulation of the homocysteine concentration. Betaine is synthesised in the liver from choline in a reaction that is catalysed by choline oxidase.  











A number of studies have been performed on humans to assess the association between certain nutrients or nutrient patterns and the risk of ALD, with conflicting results. Studies by Corrao, including case-control comparisons, revealed no significant differences in nutritional status or average intake of energy, carbohydrates, lipids and proteins. As already reported  ADDIN EN.CITE [98-100], an increased possibility of malnutrition is not a determining factor in the risk of cirrhosis, but rather is probably a consequence of progressive chronic liver disease. However, there is evidence that a pattern of higher lipid but lower protein and carbohydrate intake is significantly associated with the risk of alcoholic cirrhosis  ADDIN EN.CITE [101, 102].

A case-control (non-heavy drinkers) study on nutrient intake and nutritional patterns in Italian patients with alcoholic cirrhosis suggested that a diet rich in fruit and vegetables was beneficial, compared to one rich in animal and non-fruit sugar products  ADDIN EN.CITE [103]. No studies have been conducted comparing heavy drinkers with and without ALD.

C.	Obesity
The role of obesity as a risk factor in the development of ALD remains controversial. Many observations, however, do suggest being overweight to be an independent factor in the development of ALD  ADDIN EN.CITE [104-107]. The Dionysos study did not disclose any association between body weight or body mass index (BMI) and risk of ALD. A recent study from Japan of 266 ALD patients found cirrhotic males to be less obese than non-cirrhotic ones. No differences were detected among females [108].
 
D.	Antioxidants
Oxidants and antioxidants in alcohol-induced liver disease are poorly studied [109]. ALD is associated (possibly through malnutrition) with depletion of endogenous antioxidants (glutathione, vitamins A, E and C and selenium), which is thought to contribute to oxidative stress. 
Metadoxine, an antioxidant with few known side effects, has been approved for use in the treatment of ALD in some countries. A controlled trial from Spain showed greater 


Overall improvement in markers of liver function and more rapid response to therapy in the treated group compared to a group given a placebo  ADDIN EN.CITE [110]. Further evidence regarding their role in ALD pathogenesis is needed.
 
 (5) Drugs
NAFL and/or steatohepatitis have been associated with several drugs including amiodarone and anti-retroviral agents  ADDIN EN.CITE [111, 112]. Other drugs such as paracetamol, isoniazid and methotrexate  ADDIN EN.CITE [113-115] are more likely to cause acute liver injury when there is pre-existing liver disease. However, there has been no systematic case-control study of the associations between prescribed medications and development of D-ALD.

 (6) Social class 




Chapter 2: Hypothesis, Aims and Methods

The hypothesis of this study is that the development of ALD in heavy alcohol drinkers is variable and that a number of potential environmental factors must play a role in this disease.

To investigate this hypothesis, we had three main aims:
Firstly: to assess familial predisposition to ALD through drinking behaviour and presence of liver disease in relatives. 
Secondly: to assess the association of environmental factors with ALD – these included: 
(a) Early life events, including prematurity and birthweight based on maternal recall and validated by available records, (b) cigarette consumption and (c) lifetime alcohol intake, total and individual beverages. A case-control strategy was used for the above.




Definite D-ALD (liver failure) was determined if each of the following conditions was present:
(a)	 First episode of liver decompensation occurred between 01/04/1998 and 31/03/2008. Decompensation is liver failure which can be described using the Child-Pugh classification. 

[The Child-Pugh score uses five clinical features to assess the severity of liver disease: three biochemical (prothrombin time, albumin and bilirubin) and two clinical (encephalopathy and ascites), with cases given a grade of A, B or C. Class A indicates relatively mild disease, whilst inclusion cases are class B or C.]  
(b) Alcohol intake of > 60 units/wk (men) or 40 units/wk (women) for at least five years.  
(c) Either liver biopsy consistent with ALD or all of the following present in those who did not have a biopsy:
(i) Normal serum ferritin or iron saturation or absence of C282Y homozygosity; (ii) Serum negative for hepatitis B surface antigen and hepatitis C antibody, antinuclear and antimitochondrial (or M2) antibodies; (iii) Normal serum alpha-1 antripsin level or absence of ZZ phenotype; and (iv) In those under 40 years of age, normal serum caeruloplasmin or 24 h urinary copper.

 The following groups were excluded: 
(1) Those who had mild liver decompensation, that is Child’s-Pugh class A.
(2) Those with test results suggesting other liver diseases.
(3) Those who developed ALD at lower reported levels of alcohol consumption. 

2.2 Control Definition 

All controls met the following criteria:
(A) Alcohol consumption criteria (60 U/wk (men) or 40 U/wk (women) for >5 yr).
(B) No evidence of liver disease: (i) on history or clinical examination, (ii) normal serum bilirubin, albumin, prothrombin time and (iii) normal or “bright” liver texture, no splenomegaly or ascites, smooth liver edge, normal caudate lobe volume and portal vein flow. Controls had to be health care seeking individuals presenting to Sheffield Teaching Hospitals (STH) (both RHH and NGH sites), Sheffield Alcohol Services and Sheffield-based GP surgeries. We did not recruit partners or relatives of subjects.

3.3 Interventions and Data Collection 

(1) Information sheets were given to and consent forms signed by all subjects (including mothers when possible as some of the early life data were collected from them).

(2) Questionnaires were given by hand or mailed to subjects requesting data on: 
a. Lifetime alcohol consumption (modified timeline follow-back method) [119] which included the average weekly consumption of alcohol for each stable phase in life. 
b. Early life: Birthweight (based on maternal recall and hospital records where possible), early life social circumstances, childhood diseases, immunisations, early adult life weight, other medical conditions and employment history.
c. Smoking history expressed as average number smoked per each phase in life and type of smoking, i.e. cigarette, pipe, etc.

(3) We obtained recorded data on height, weight, presence of diabetes, blood pressure and serum lipids at least one year prior to the onset of symptoms of D-ALD.

(4) Health care seeking controls had a clinical examination, liver blood tests and an abdominal ultrasound (performed by Dr Rob Peck at RHH, others at NGH) to exclude serious liver disease.

(5) Where the case was deceased, we attempted to identify a living first-degree relative via the patients last stated GP, with a view to obtaining permission to view GP records. This was carried out via the clinician who was in charge of the patients.  

Data on cases and controls were stored on a computer database at the RHH using Microsoft Office 2007 (Excel, Access and Word – Microsoft Corporation), statistical analysis and variable comparison were carried out using relative risk (RR), chi-squared test and the SPSS 16.0 for Windows package (SPSS Inc. Chicago IL, USA).
The references and bibliography were sorted by Endnote X1 (by Thomson-Reuters).

All subjects gave written informed consent. The study was approved by the South Sheffield Research Ethics Committee (SSREC) in 1996 (SSEC number 96/297). 
















Chapter 3: Familial Predisposition to ALD


        
3.1 Background 
Only a minority of heavy drinkers develop ALD. There is evidence to support genetic predisposition as explained in Chapter 1. Some of the evidence, especially from association studies, was inconclusive.

Familial predisposition to a disease is supportive of genetic predisposition, although it may also result from shared environmental cofactors. Conversely, absence of a family association would suggest that genetic predisposition to the disease in question may not be strong. 

Several chronic inflammatory diseases are associated with familial clustering, one measure of which is lambda (λ) or risk ratio [120]. For example, sibling risk ratio (λs or the ratio of disease prevalence in siblings of those with the disease over prevalence in the general population) has been reported as between 7 and 15 for rheumatoid arthritis [121], primary biliary cirrhosis (PBC) [122], ulcerative colitis [123] [124] and insulin-dependent diabetes [125]. λr (for first-degree relatives in general) has been reported as 9.5–18 for PBC [122], ulcerative colitis and Crohn’s disease [124]. Familial clustering also exists in lung cancer, a disease analogous to ALD in that it has a clear environmental determinant (smoking), but affects only a minority of smokers, with a reported λs of 2  ADDIN EN.CITE [126]. We are unaware of any studies assessing familial clustering in ALD.
In this chapter I report the prevalence of definite or possible liver disease in relatives (and also in HD relatives) of cases with D-ALD, compared to that in relatives of controls, in order to assess the novel question of familial clustering in ALD.  

3.2 Materials and Methods
The initial information was collected as part of case-control studies on genetic and environmental factors predisposing to ALD. This was further expanded with my recruitment covering a total of 11 years from 1998 to 2009. All subjects gave written informed consent. 

Cases had to satisfy inclusion criteria as per the methods section. Of the 291 cases included in the present study (see results), Hepatitis B Virus (HBV) antigens and Hepatitis C Virus (HCV) antibodies were absent from the serum of all (except for one in whom the tests were not carried out). Antimitochondrial antibodies were absent in all but two patients (one had a biopsy confirming ALD). Antinuclear antibodies were absent in all but eight patients (five positive and three weak positive), three of whom had a liver biopsy consistent with ALD. Anti-smooth muscle antibodies were positive in 14 patients, weakly positive in 18 and not done in four; biopsies performed in 12 out of these 36 patients were consistent with ALD. A total of 283 out of the 291 patients had either: (a) at least one normal serum ferritin or iron saturation, (b) were not C282Y homozygous on haemochromatosis HFE genotyping or (c) had a liver biopsy ruling out haemochromatosis. We have previously reported on the rarity of haemochromatosis (<1%) in patients with apparent ALD  ADDIN EN.CITE [127]. Serum alpha 1 antitrypsin was > 1.0 (g/L) in 271 of the 274 cases tested; the remaining three had phenotype MS/MZ. Of the 81 patients aged ≤ 40 years, 72 had a normal serum careuloplasmin or 24-hour urine copper. Of the remaining nine, three had a biopsy consistent with ALD, two had marginally low serum caeruloplasmin (urinary copper not done) and four had no copper studies done.

All cases had an abdominal ultrasound scan (Table 1). In 21 cases scans were normal (n=5) or showed a bright liver echo texture only (n=16). In the remaining patients, the scan showed a combination features suggestive of cirrhosis and liver disease including heterogeneous texture, irregular edge, hepatomegaly, splenomegaly, ascites, retrograde portal vein flow and/or varices.(Appendix Table 1). No patient had biliary obstruction or malignancy. 

Table 1: Ultrasound findings of cases 
ultrasound findings of cases	Number (%)
Normal	5 (2)
Bright liver	16 (5)
Features suggestive of liver disease	270 (93)


Liver histology was available in 84 patients (29%), and was consistent with ALD in all of these. Thirty-four (40%) had alcoholic hepatitis, 52 (62%) had cirrhosis and a further 23 (27%) had bridging fibrosis. In the remaining 207 patients who did not have a biopsy, 139 (67%) had either ascites or varices, features previously taken to suggest the presence of cirrhosis [65]. Intermittent hepatic encephalopathy grade I–II was present in 31 cases and grade III–IV in seven. 


Controls also had to satisfy inclusion criteria. Of the 208 heavy-drinking controls included in this study (Table 2) 129 (62%) were health care seekers, including ex-alcohol abusers living in “dry” houses (n=17) and those attending local alcohol services and help groups (n=33), general practice (n=6), or acute hospital services (n=73). Of the latter, 16 had presented with alcohol related problem (pancreatitis, neuropathy, myopathy, alcohol withdrawal, gastritis, gynaecomastia and cardiomyopathy). In addition, we recruited 77 heavy drinking, but non healthcare-seeking, community controls, including patients’ spouses (n=8), friends (n=8), 
hospital staff (n=3) and those replying to advertisement in press and radio (n=58). In two of the controls, the source of recruitment was not documented

Table 2: Source of recruitment for controls 

Source of control recruitment (n=208)	N (%)
Health care seeking:	129 (62)
   -Acute hospital admissions	73 ( 35)
   -Alcohol services	33 ( 16)
   -dry houses	17  ( 8)
   -General practice	6 ( 3)
Non health care seeking (i.e. patient spouses and friends )	77 ( 37)
unknown 	2 ( 1)

All control subjects had (1) average weekly alcohol consumption of more than 60 units (men) and 40 units (women) per week for at least 5 years previously. (2) There was no evidence of liver disease, defined by each of: (a) no past/present symptoms/signs of liver disease; (b) normal serum albumin, bilirubin and
prothrombin time; and (c) an abdominal ultrasound showing smooth liver edge and normal or bright (not heterogonous) liver texture, no splenomegaly or ascites. (The presence of a regular liver edge was 90% exclusive of cirrhosis in previous studies  ADDIN EN.CITE [128, 129].) Although not a requirement for inclusion, platelet count was < 150 (x109/L) in five of the 208 controls and < 120 (x109/L) in two. PGA index (calculated from prothrombin time (P) serum gamma-GT(G) and apolipoprotein B1 (A)) was also calculated. (A PGA value of < 6 is 90% exclusive of cirrhosis [130].) It was measured in 149 (72%) controls and was less than 6 in all but 18 (a PGA score of 6 in 16 controls, and a score of 7 in two). Only one control from these 18 had a platelet count less than 150 and in those who did not have a PGA value (28%), just three had an abnormal platelet count. 

All subjects were asked to complete lifetime alcohol questionnaires [131] regarding the type and amount of alcohol consumed weekly during different stages in life. From this, we calculated total lifetime alcohol consumption and average weekly alcohol intake, as described previously  ADDIN EN.CITE [127, 132]. Subjects were also asked to complete a pro forma in relation to alcohol consumption and presence of liver disease in their (unidentified) parents and siblings. No data were collected on offspring, who were deemed unlikely to be informative, given that most subjects were young or middle-aged (average age 47–49 years). The subject was asked to grade his/her relatives’ drinking behaviour as abstinent, light/social, moderate or heavy (with no formal instructions given as to what these terms meant). We also asked the subjects if any of their relatives had “liver disease”, and if so, what type. Subjects were also asked whether their relatives were alive or not, and, if deceased, the cause of death. This information was unavailable in the same percentage (15.6%) of all relatives of cases and controls. Any subjects who indicated on the questionnaire that they had or thought they had a parent or sibling with liver disease, but for whom data were incomplete, were subsequently contacted by phone or in clinic (by one of the investigators, AA or DG, the latter of whom was also the physician in charge of the patients with ALD) to assess whether or not this relative had ALD. Definite ALD was defined as one or more of the following in a relative labelled as a heavy drinker: jaundice, ascites, gastrointestinal bleed or being told by a doctor that they had cirrhosis of the liver. Possible ALD was defined as other liver disease consistent with ALD in a heavy drinker when these features were not known to be present. Non-ALD was defined as liver disease other than ALD. In some cases, with the subject’s permission, discussions were held with unaffected immediate family members. No attempts were made to contact potentially affected relatives directly.

We compared the prevalence of (a) all liver disease, (b) all ALD (definite and probable) and (c) definite ALD in relatives of HD cases, with prevalence in relatives of HD controls.

Data were expressed as odds ratio (OR) values ± 95% confidence intervals. Similar comparisons were made between various subgroups of cases and controls. Statistical 




3.3.1 Comparison of patients and controls:
 In total, 334 patients with D-ALD were recruited. A total of 295 (87.1%) returned a family history questionnaire. Of these, one was not interpretable and three were non-informative, as the subjects had been adopted. The remaining 291 were included and had a total of 1,237 relatives, 1,123 (90.8%) of which were informative: 48% parents, 25% brothers and 27% sisters.
Of the 224 unrelated HD controls recruited, 209 (93%) returned a family history questionnaire, one of which was not informative as the subject was adopted. The remaining 208 controls were included and had 866 relatives, of which 833 (96.2%) were informative. The percentages of parents, brothers and sisters were 48%, 28.3% and 23.7%, respectively.
Patients returning the questionnaire had severe ALD, as manifested by the parameters of liver dysfunction (Table 3). There were more men than women controls; however, lifetime alcohol consumption and age did not differ significantly between the two groups. 

3.3.2 Drinking behaviour:  









Table 3:  Patient and Control groups, Baseline Characteristics [Mean +/- Standard Deviation presented]
	Patients(n=291)	P Value	Controls(n=208)
Men (%)	192 (66%)	0.04	155 (74%)
Age (Years)	47.1± 9.9	0.08	48.7 ± 9.8
BMI (number)	23.8 ± 4.9 (144)	0.002	25.6 ± 4.7 (167)
Number with diabetes (%) 	13/221 (5.9)	0.20 	5/164 (3.0)
Child-Pugh score (number)	10.2 ± 1.9 (274)	-	-
Maddrey Discriminant factor (number)	32 ± 30 (272)	-	-
Total lifetime alcohol intake (units x 10³)	146 ±104	0.48	153 ±98
Average weekly alcohol intake (unit/week)	99 ± 67	0.77	97 ± 60
AST/ALT ratio on presentation	3.3 ± 1.6	<0.001	1.1 ± 0.4
Serum Bilirubin µm/L	181 ± 182	<0.001	13 ± 6
Serum Albumin gram/L	27 ± 5	<0.001	43 ± 4
Prothrombin time (seconds)	16.5 ± 5.6	<0.001	10.4 ± 0.5





Table 4: Drinking patterns among relatives of cases, compared to relatives of controls
	Relatives of Patients(% of informative)	χ2	Relatives of Controls(% of informative)
Abstinent 	177 (15.8)	0.03; ns	134 (16.1)
Light/social	398 (35.4)	0.8; ns	312 (37.4)
Moderate	342 (30.4)	3.2; ns	223 (26.7)
Heavy	206 (18.3)	0.5; ns	164 (19.7)
ns: not significant





Thirty-seven relatives of 33 patients (3.3% of all informative relatives) were identified in the questionnaire as having liver disease (Appendix, Table 2). Five relatives (four heavy drinkers and one moderate drinker) were excluded as further discussion with the patient and family members revealed no evidence of liver disease (one had cancer, one had angina and another died of pneumonia, with no further information on the remaining two).
Eight of the remaining 32 relatives (none of whom were heavy drinkers) were considered, following discussions with the patients and family, to have liver disease but not ALD (one had liver cysts, one non-alcoholic fatty liver disease, two had PBC, had one colon cancer with liver metastasis and three had “liver cancer”). 
However, in addition to the 24 relatives with ALD, we included two more relatives (Appendix, Table 2 – numbers 21 and 22) who were not reported as having liver disease in the questionnaire but who presented to us independently with D-ALD. In the pro forma, one relative was reported as a light drinker, while the other’s drinking pattern was not known.





Prevalence values for any liver disease, for definite ALD and for definite or possible ALD were slightly higher in relatives of cases than relatives of controls (Table 5). However, the differences were not significant, with an OR between 1.0 and 1.3 and 95% CI values easily overlapping unity. As also shown in Table 3, the OR remained about unity if (a) presence of liver disease or of ALD was based on questionnaire data only (uncorrected by subsequent enquiries), (b) analysis was confined to (i) subjects for whom data were available on all relatives or (ii) subjects for whom cause of death was ascertained in all deceased relatives. 
We also compared the prevalence of all liver disease and of ALD in various case and control subgroups (Table 6). When analysis was confined to patients with Child C liver disease, or to male subjects only, the patient/control OR remained around unity. The same result was observed when confining analysis to parents, however confining analysis to siblings yielded an OR of 1.5. In the subgroups of only male relatives or relatives of subjects less than 50 years old, the OR was also slightly higher at 1.3 but was still not significantly different from unity. 











Table 5: Prevalence of liver disease, defined by various criteria, in first-degree relatives: 
comparison between cases and controls. 
		Patients	OR (95% CI)	controls
All subjects, all sources:
All liver disease* (% of info)	34/1125 (3.0)	1.0 (0.60-1.7)	25/833 (3.0)
All ALD* (% of HD)	26/208 (12.5)	1.09 (0.58-2.0)	19/164 (11.6)
Definite ALD* (% of HD)	22/208 (10.6)	1.27 (0.63-2.6)	14/164 (8.5)
All subjects, questionnaire data only:
All liver disease** (% of info)	37/1123 (3.3)	1.06 (0.63-1.8)	26/834 (3.1)
ALD** (% of HD)	37/206 (18.0)	1.17 (0.67-2.0)	26/165 (15.7)
Subjects where data was available on all relatives:
All liver disease	26/845 (3.1)	1.0 (0.57-1.8)	22/725 (3.0)
All ALD	20/150 (13.3)	1.13 (0.56-2.3)	16/134 (11.9)
Definite ALD	18/150 (12.0)	1.27 (0.59-2.7)	13/134 (9.7)
Excluding relatives where cause of death was unknown:
All liver disease	23/949 (2.4)	0.90 (0.48-1.6)	19/703 (2.7)
All ALD	17/185 (9.2)	0.87 (0.41-1.8)	14/134 (10.4)
Definite ALD	   15 /185 (8.1)	1.09 (0.47-2.5)	10/134 (7.5)

 * Including (in cases) 2 relatives not mentioned in questionnaire presenting independently with ALD. ** Including the excluded relatives.


















Table 6: Comparison of the prevalence of liver disease between case and control subgroups
	Patients	OR (95% CI)	Controls
Parents:
All liver disease (% of relatives)	18/539 (3.3)	0.95 (0.47-1.9)	14/400 (3.5)
ALD (% of HD)	12/109 (11.0)	0.80 (0.33-2.0)	10/75 (13.3)
Siblings:
All liver disease (% of relatives)	16/584 (2.7)	1.08 (0.50-2.3)	11/433 (2.5)
ALD (% of HD)	14/97 (14.4)	1.5 (0.61-3.7)	9/89 (10.1)
Relatives of subjects (cases) with Child C disease:
All liver disease (% relatives)	14/507 (2.8)	0.92 (0.47-1.8)	25/833 (3.0)
All ALD (% of HD)	10/92 (11.0)	0.93 (0.41-2.1)	19/164 (11.6)
Relatives of subjects under 50:
All liver disease (% relatives)	24/743 (3.2)	0.91 (0.48-1.7)	17/482 (3.5)
All ALD (% of HD)	20/152 (13.2)	1.30 (0.60-2.9)	11/106 (10.4)
Male relatives:
All liver disease (% of relatives)	19/549 (3.5)	1.08 (0.53-2.2)	14/436 (3.2)
All ALD (% of HD)	17/132 (12.9)	1.35 (0.62-3.0)	12/122 (9.8)
Male patients:			
All liver disease (% of relatives)	17/732 (2.3)	1.13 (0.54-2.3)	13/630 (2.1)
All ALD (% of HD)	14/146 (9.6)	1.05 (0.50-2.4)	11/120 (9.2)

info: informative, HD: Heavy drinkers.

3.4 Discussion  
In this analysis we sought to assess whether development of ALD in heavy drinkers exhibited familial clustering, which might suggest genetic predisposition. The main finding was that there did not appear to be significant familial clustering of ALD. 
Our results are in contrast to similar case-control studies in several other chronic diseases  ADDIN EN.CITE [121-125] where disease prevalence in relatives is increased several-fold relative to the general population.
This can be further explained by comparing our results to studies of heavy drinkers in general populations  ADDIN EN.CITE [35, 58]. In an Italian population study [58], prevalence of cirrhotic liver disease in heavy drinkers (> 90 gram/day or 79 units/week) was 5.9% (15/254). In a Danish population study [35], prevalence of cirrhotic ALD in heavy drinkers (> 70 gram/day or 60 units/week) was 7.4% (17/231). Comparing the prevalence in our study of “definite ALD” in HD first-degree relatives of ALD patients (22/208) to these values gives RR values (i.e. λr) of 1.79 and 1.44, respectively. Whilst such comparisons are limited by different populations and study designs, they support our finding that HD relatives of patients with ALD are not at substantially increased risk of developing ALD compared to those without a family history of ALD.

The strengths of the data are due, firstly, to their large size (almost 500 subjects and almost 2,000 relatives); secondly, to the matching of patients and controls (who represent the same population studied) for age and lifetime alcohol consumption, which could be important for assessment of cofactors predisposing to ALD; and, thirdly, the detailed characterisation of the patients and controls as two HD cohorts with widely differing susceptibility to development of ALD. 

The patients all had severe (decompensated) liver disease, and although liver histology was not available in all, other liver diseases were adequately excluded in nearly all patients by specific biochemical, serological and radiological evaluation.  

On the other hand, the HD controls are likely to have had fatty liver infiltration, seen in most heavy drinkers, but not to have had hepatic decompensation and (although they did not undergo liver biopsy) are very unlikely to have had cirrhosis. Controls were recruited prospectively over the same time period and from the same eligible population: although the controls cohort contained a higher proportion of men than that of patients, the cohorts were not significantly different with regard to age and lifetime alcohol consumption.  

The main limitation to the study is that information on relatives was based on the accounts of the probands. The limits set out by the ethics committee approval did not allow us to approach relatives, access their records or identify them. Probands often explicitly stated that they did not want us to approach their families. We cannot envisage a similar study involving the collection of information directly from affected relatives as being either ethically or logistically feasible. Thus, inevitably, categorisation of alcohol drinking behaviour among relatives was crude. However, this is unlikely to have differed systematically between the cases and controls. Furthermore, given that HD has a familial component [61], the results are as expected in regard to the prevalence of HD in relatives of both cohorts being similar to one another and four- to tenfold higher than its prevalence in the general population  ADDIN EN.CITE [35, 58]. Also, as expected, prevalence of HD is higher in male than in female relatives. Finally, as we have previously reported [133], the presence of multiple HD relatives was associated with high dependence scores in the probands, providing some further validation of the data.

We went to considerable lengths to contact subjects who indicated they had a relative with liver disease and succeeded in checking the information in nearly all subjects (supplementary Tables 2 and 3) . However, categorisation of liver disease in relatives was also inevitably crude. Milder forms of liver disease are often occult, thus the total prevalence of any liver disease in relatives will certainly have been under-reported. However, we adopted a definition of definite liver disease in relatives which should have been clinically manifest and of which most family members should thus have been aware. Also, we had very limited information of the aetiology of the relatives’ liver disease. However, based on our categorisation of the current cohort of probands with ALD, which involved detailed non-invasive screening, over 90% of HD patients in the north of England with decompensated liver disease actually have ALD, thereby justifying our pragmatic definition of ALD as liver disease in an HD relative.  

Indeed, there are some unavoidable potential biases in this study which might increase the detection rate of ALD in relatives of patients compared to controls. Subjects with ALD are potentially more aware of the manifestations of decompensated liver disease and this may increase their ability to recall such features in an HD relative. Also, with patients, especially those under regular follow-up, we are more likely to know about relationships with other cases, compared to controls whom we met only once or twice. Indeed, we included in the questionnaire two relatives of cases who were not identified as heavy drinkers with liver disease, but who presented independently to us with D-ALD. Finally, the finding of severe ALD in a subject may result in his/her HD relatives themselves seeking medical attention, thereby increasing the possibility of diagnosis of ALD. However, despite these potential recall biases, our results still suggest a broadly similar prevalence of liver disease in first-degree relatives of heavy drinkers with and without liver disease. 
Furthermore, we tried to address the unavoidable limitations in our data by comparing patients and controls in several different ways (Tables 5 and 6). The message from all these comparisons was consistent. That is, prevalence of liver disease in relatives of subjects with severe ALD is only slightly, and not significantly (OR of 1–1.5, 95% CIs overlapping unity) higher than that in relatives of heavy drinkers without ALD. 
Although not statistically different from unity, the patient/control OR for ALD prevalence in HD relatives did sometimes modestly exceed unity. Despite studying almost 500 subjects, we found only 370 HD relatives (Table 4), which limited statistical power. Our upper 95% confidence limits for OR (Tables 5–6) are between 1.6 and 3.0, raising the possibility of a type-II statistical error. Thus, it is possible that the variable predisposition to develop serious liver disease in heavy drinkers has some familial association and, therefore, some genetic component. What we can surmise however from our results is that this genetic predisposition is likely to be modest. This is supported by the results of a reanalysis [134] of a large twin study [59] which concluded that much of the previously observed difference in concordance rates for cirrhosis between monozygotic and dizygotic twins was due to differences in drinking behaviour. Additional larger studies would be useful in assessing this further, including similarly designed studies in other parts of the world and, also, whole-genome association studies of well-phenotyped ALD.  









The data presented in the previous chapter suggested that the variable predisposition to develop severe liver disease in a heavy drinker is unlikely to be explained by differences in genetic predisposition and therefore environmental cofactors may be relevant. In this chapter we examine associations between ALD and early life environmental factors. 

The ‘foetal origins hypothesis’, or programming, suggests that the presence of adverse influences during intrauterine life leads to permanent alterations in foetal structure and physiology which predispose to adult disease [135].

Markers of an unfavourable intrauterine environment include growth retardation in term babies manifested by birthweight or being born before term/early (prematurity). 

Many studies have shown links between these markers and health outcomes later in life. Low birthweight has been found to be associated with an increased risk of CHD [136], early onset of end-stage renal disease, impaired glucose tolerance and higher insulin resistance  [137]. Prematurity was linked to raised blood pressure [138] and insulin resistance [139].

On the other hand, large birth size seems to increase the risk of rheumatoid arthritis [140] and obesity [141]. Yet no relation has been found between birthweight and immune conditions like Systemic Lopus erythematosis (SLE) [142] or thyroid autoimmunity (A study in Twins) [143].

Some of these later-life conditions, such as type 2 diabetes and obesity, have been linked to liver disease like NASH  and ALD but little is known about the link (if any) between birth weight/age and the risk of developing ALD or indeed any liver disease.
(An Italian study in children has shown low birth weight to be an independent risk factor for NAFLD with OR = 7 [144] (they studied 90 children with NAFLD who were followed prospectively for two years), the control group had 90 children pair matched by age and sex, subjects’ average age was 11 and all were born at term.) 

In this case-control study we explored the perinatal characteristics of two groups of heavy drinkers with and without liver disease to assess if these were associated with the risk of developing ALD.

A study in Sheffield showed that people who were small at birth because they failed to grow, rather than because they were born early, were at increased risk of CHD [136].





As with the previous chapter, initial information was collected as part of case-control studies on genetic and environmental factors predisposing to ALD and which was further expanded using my recruitment covering the period from 1998 - 2010.  
All patients were heavy drinkers with alcohol intake of > 60 units/wk for men or > 40 units/wk for women for at least five years. Cases had evidence of significant liver disease with Child-Pugh scores B or C and blood and/or biopsy evidence of this and no other liver disease. Controls had no clinical, biochemical or radiological evidence of ALD. Ethical approval was as outlined above and all subjects gave written informed consent. 

A total of 215 patients (cases) were included, meeting the inclusion criteria as given above. All patients had an abdominal ultrasound scan. In 18, the scan was normal (n=5) or showed a bright liver echo texture only (n=13). In the remaining patients, the scan showed a combination of heterogeneous texture, irregular edge, hepatomegaly, splenomegaly, ascites, retrograde portal vein flow and/or varices. No patient had biliary obstruction or malignancy. 

Liver histology was available in 48 patients (22.3%) and was consistent with ALD in all. Twenty-two (46%) had alcoholic hepatitis, 22 (60%) had cirrhosis and a further 11 (23%) had bridging fibrosis. In the remaining 167 patients who did not have a biopsy, 107 (64%) had either ascites or varices, features previously taken to suggest the presence of cirrhosis. Twenty (12%) had features of fibrotic, coarse, nodular or heterogeneous-looking liver. Hepatic encephalopathy grade I–II was present in 19 cases and grade III–IV in five. 
We also recruited 163 controls, as per the inclusion criteria. Of these, 115 (70%) were health care seekers, including ex-alcohol abusers living in “dry” houses (n=13) and those attending Sheffield alcohol services and help groups (n=28), general practice (n=15) or acute hospital services (n=59). In addition, we recruited 46 HD, but non-health care seeking, controls, including patients’ spouses (n=6), friends (n=6), hospital staff (n=1), ward visitors (n=2) and those replying to posters and press and radio advertisements (n=31). The source was not documented in two more controls.

As described above, all subjects were asked to complete a lifetime alcohol consumption questionnaire. They were also asked to complete a pro forma of various environmental factors. Those related to pregnancy included: birthweight, gestational age, mother’s smoking status during pregnancy (yes or no question; this was not quantified), place of birth and whether or not the mother was alive and if the subject was still in contact with her. The data were often recalled by subjects, following discussion with the mother where possible.
 
To validate this, we used subject date and place of birth to access the maternity records of mothers. For those born in Sheffield, records were stored in three hospitals (Nether Edge, Royal Hallamshire and Northern General).
 Unfortunately, many were missing due to damage sustained to records in the main maternity hospital a number of years previously.

Birthweight in term babies was classified as very low (< 1.5 kg), low (1.5–2.5 kg), normal (2.5–4 kg) and high (> 4 kg). Prematurity was classified as babies born before 37 completed weeks of pregnancy.
 




Of the 215 patients and 163 controls recruited, there were more men in the controls group than cases and they had a significantly higher BMI. Both groups, however, had comparable levels of alcohol intake and the cases clearly had significant underlying liver disease (Table 1).
Dates of birth were in the ranges 1934–1983 for patients and 1934–1980 for controls. Where data were available, subjects’ mothers were alive in exactly the same percentages (61%) and in both groups most were in touch with their mothers (124/132 for patients and 95/100 for controls).
 




Table 1: Demographics   
	Cases(n=215)	P Value	Controls(n=163)
Men (%)	136 (63.2%)	0.003	126 (77.3%)
Age (mean ± SD) (Yrs)	46 ± 9	0.20	47 ± 10
BMI (number)	24.1 ± 4.9 (136)	0.01	25.5 ± 4.7 (150)
Number with diabetes (%) 	8/147 (5.4)	0.09	2/126 (1.6)
Child-Pugh score (number)	10.2 ± 2.0 (195)	-	-
Maddrey Discriminant factor (number)	31 ± 27 (200)	-	-
Total lifetime alcohol intake (units x 10³)	135 ± 84	0.13	154 ±110
Average weekly alcohol intake (units/wk)	98 ± 65	0.85	99 ± 63
AST/ALT ratio on presentation	3.2 ± 1.6	<0.001	1.1 ± 0.4
Serum Bilirubin µm/L	175 ± 176	<0.001	13 ± 5
Serum Albumin gram/L	27 ± 6	<0.001	42 ± 4
Prothrombin time (seconds)	16.2 ± 5.4	<0.001	10.4 ± 0.5
Ultrasound: normal or fatty liver only	18	<0.001	163


There were no significant differences between both groups for all categories compared (Table 2). This was also true when comparison was limited to patients with Child C disease only (Table 3). Regression analysis showed no difference in birthweight between cases and controls after correcting for age, gender and BMI. We also found no difference between the two groups’ maternal age when comparison included all patients or those with Child C liver disease only.
Males in general were heavier at birth than females, a fact that has been observed in general populations [men (n=262) birthweight (mean kg ± SD) 3.26 ± 0.76, women (n=116) 3.10 ± 0.69]. This can be attributed to many factors [145].
There were also no differences in birthweight or prevalence of low birthweight between cases and controls when analysis was confined to males or to females only.

Although smoking has been identified as a risk factor for low birth weight (LBW), it did not affect the birthweight of cases or controls in this study (p=0.96 and 0.76 respectively and 0.8 for all subjects pooled together).

Table 2: Comparison of birthweight and mothers’ smoking characteristics between all cases and controls 
	Cases (215)	P	Controls (163)
Premature delivery (gestational age < 37 weeks) (%)	17/200 (8.5)	NS	11/148 (7.4)
Very low/low/normal/high birthweight distribution 	6/25/159/25 	NS	5/14/130/14
Birthweight in kg (n)	3.2 ± 0.74 (215)	NS	3.2 ± 0.75 (163)
Birthweight (kg) in full-term babies (n)	3.3 ± 0.64(183)	NS	3.4 ± 0.61 (137)
Birthweight/gestational age ratio (gram/wk) (n)	81 ± 17 (200)	NS	83 ± 17 (148)
Mother smoking during pregnancy (%)	72/148 (48.6)	NS	48/109 (44.0)








Table 3: Comparison of birthweight and mothers’ smoking characteristics between Child C cases only and controls 
	Cases (124)	P	Controls (163)
Premature delivery (gestational age < 37 weeks) (%)	9/115 (7.8)	NS	11/148 (7.4)
Very low/low/normal/high birthweight distribution 	3/14/94/13	NS	5/14/130/14
Birthweight in kg (n)	3.2 ± 0.7 (124)	NS	3.2 ± 0.75 (163)
Birthweight (kg) in full-term babies (n)	3.3 ± 0.64 (106)	NS	3.4 ± 0.61 (137)
Birthweight/gestational age ratio (gram/wk) (n)	81 ± 17 (115)	NS	83 ± 17 (148)
Mother smoking during pregnancy (%)	37/89 (41.6)	NS	48/109 (44.0)


















Table 4: Recalled and actual birthweight data (in kilograms)
						































This is an attempt to explore environmental factors predisposing to ALD and we can conclude that potential factors are probably in play later in life. 
 
All of the cases had decompensated liver disease and were likely to have had underlying cirrhosis, as evidenced by biochemical parameters, histology and radiology.  
On the other hand, the controls were unlikely to have had severe liver disease. They were recruited prospectively over the same time period and from the same eligible population. We are satisfied we have ruled out other liver disease in patients and controls. 

We recruited 387 subjects into two groups and despite the significant difference in the severity of underlying liver disease, both groups were comparable in many aspects, which further strengthens the results. These include alcohol intake, gender and age group. The same percentage of subjects were born in Sheffield (and South Yorkshire), hence we could assume no differences in any potential geographical factors influencing intrauterine life. In addition, the same percentages were in contact with their mothers in both  groups
 
A key factor in this study is that the birthweight data were recalled, raising possible concern about patients’ ability to accurately remember these, especially in cases who were potentially ill.
Firstly, when recruiting patients, they had to be stable clinically and not immediately 
following an acute admission. They had to be alert during a process involving the completion of a number of questionnaires. The majority of cases had no encephalopathy at the time of their worst blood results.

Secondly, we encouraged subjects to discuss the birth weight with their mother or other family members when possible, and on a number of occasions data were collected in the few days following such discussion. 

When we compared these to real figures, the correlation was very significant. In the relatively small sample where actual birthweight was obtained from clinical records, correlation with the recalled birthweight was very strong. This type of information is relatively harder for patients to remember than, for example, whether or not they were born prematurely. Barker and colleagues (1993) managed to acquire the birthweight details of more than 1,500 men born at the Jessop Hospital in Sheffield between 1907 and 1924 [136]. Unfortunately, we did not have similar such success in tracing birth records despite the fact that a number of our subjects were born at the same hospital. In addition, many of our patients were born either at home or outside Sheffield.

Another observation is the mother’s smoking habit, which was crude yet there were no differences in total percentages between the two groups. 

In conclusion, even though no link has been found, environmental factors contributing to ALD are poorly understood and this was an important step towards understanding the variable’s risk to ALD. Future research into other potential factors is crucial. 






Multiple studies have shown only a small percentage of even heavy drinkers develop ALD. In the previous two chapters I concluded that the genetic effect on susceptibility to ALD is modest. I also found no evidence to suggest that intrauterine characteristics contributed to such risk. In this chapter I explore the role of an important environmental factor; tobacco/ nicotine smoking.   

Cigarette smoking is thought to be damaging to the liver. The proposed mechanism is by an inducing effect upon the cytochrome P-450 system in the liver, resulting in the impairment of clearance of certain drugs [146]. This system is also important in the metabolism of potentially hepatotoxic drugs like acetaminophen and non-steroidal anti-inflammatory drugs. Smoking was also found to affect liver enzymes by increasing GGT [147].
  
Indeed, smoking has been linked to disease severity in PBC [148] . Also, there is evidence that it can accelerate damage to the liver in people infected with hepatitis C [149]. However, there is a negative association between smoking and other chronic inflammatory diseases such as Primary Sclerosing Cholangitis (PSC) [150] and ulcerative colitis [151]. Furthermore, for a condition like NAFLD, no difference in prevalence was observed between current (including heavy) smokers and non-smokers, indicating that there is no relationship between smoking and NAFLD [152].   

However, the evidence regarding smoking and alcohol is somewhat conflicting and the often strong association between smoking and drinking alcohol makes it difficult to fully understand these effects. An association between smoking and alcoholic cirrhosis has been suggested by Klatsky and colleagues [79]. They studied the traits of 128,934 adults who underwent health examinations from January 1978 to December 1985 in relation to subsequent hospitalisation or death from cirrhosis of the liver. However, the relation of cigarette smoking to alcoholic cirrhosis was not progressive with increasing smoking in either sex (i.e. the increased risks associated with cigarette smoking were similar for smokers of less than one pack per day and of one or more packs per day). Lighter cigarette smoking (less than one pack per day) was weakly related to non-alcoholic cirrhosis, but the smoking of one or more packs of cigarettes per day was not related. A case-control study showed a dose–effect relationship and therefore the possibility of smoking being a small risk factor for cirrhosis. The OR (95% CI) was 1.9 (1–3.6) at an average lifetime daily smoking of 20 cigarettes or when comparing a small number of subjects (30 cases and 30 controls)  ADDIN EN.CITE [153].
Other studies found no interaction between smoking and alcohol intake on the risk of dying. Gronbaek and colleagues found that the risk function between alcohol and mortality was not modified by sex, age, BMI or smoking and remained stable over 12 years [154], confirming findings previously described by Kono et al. [155].






We recruited two cohorts of heavy alcohol drinkers fulfilling the criteria set out previously. A total of 284 cases had D-ALD; other causes of liver disease were excluded through a full liver screen, as outlined above.  
A total of 199 controls had no clinical evidence of liver disease, persistently normal serum bilirubin, albumin and prothrombin time and ultrasounds showing normal or bright liver echo-texture and no other abnormality. They were recruited prospectively from health services in Sheffield and some were non-health care seeking. 

The initial information was collected as part of case-control studies on genetic and environmental factors predisposing to ALD; this was further expanded with my recruitment covering a total of 11 years between 1998 and 2009. All subjects gave written informed consent. 

Both groups completed lifetime alcohol and environmental questionnaires as outlined in the methods section. Specifically, we collected data on the type and duration of smoking and the average number of cigarettes smoked per day at different stages in life. Subjects were classified as current, past and never smokers. Smoking use was expressed as a pack-years value, which is a unit of measuring smoking over a long period of time. It is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. A pack comprises 20 cigarettes.










Men (%)	202 (71%)	0.54	157 (76%)
Age (mean ± SD) (Yrs)	47.3 ± 9.7	0.73	47.6 ± 9.4
BMI (number)	24.1 ± 5.2 (154)	0.002	25.9 ± 5.7 (167)
Number with diabetes (%) 	13/177 (7.3)	0.30 	6/129 (4.6)
Child-Pugh score (number)	10.2 ± 1.9 (262)	-	-
Maddrey Discriminant factor (number)	30 ± 28 (264)	-	-
Total lifetime alcohol intake (units x 10³)	140 ± 94	0.35	149 ±82
Average weekly alcohol intake (units/wk)	95 ± 57	0.85	94 ± 40
AST/ALT ratio on presentation	3.0 ± 1.2	<0.001	1.1 ± 0.4
Serum Bilirubin µm/L	168 ± 176	<0.001	12 ± 5
Serum Albumin gram/L	27 ± 5	<0.001	42 ± 4
Prothrombin time (seconds)	16.4 ± 5.4	<0.001	11.0 ± 0.5
Ultrasound: normal or fatty liver only	18	<0.001	199


There were significantly more “never smokers” among cases than controls (n=94 (33%) vs 40 (20%), p =0.002). However, the percentage of current smokers was not different (n=153 cases (54%) vs n=109 controls (55%)) (Figure 1).  
 















Table 2:  Smoking habits: comparison between all cases and controls

	Cases (n=284) 	P 	Controls (n=199) 
Lifetime cigarette consumption (x 10³) (Mean ± SD) 	122 ± 140 	0.007 	146 ± 133 
SQRT of lifetime cigarette consumption 	266 ± 228	0.008	323 ± 206
Duration of smoking history in years 	16.9 ± 15.3 	0.038 	19.6 ± 13.8 





Table 3:  Smoking habits: comparison between cases (Child C only) and controls

	Cases (n=123) 	P 	Controls (n=199) 
Lifetime cigarette consumption (x 10³) (Mean ± SD) 	105 ± 134 	0.001 	146 ± 133 
Duration of smoking history (years) 	15.1 ± 14.7 	0.006 	19.6 ± 13.7 






Table 4:  Smoking habits: all cases and controls (health care seeking only)

	Cases (n=284) 	P 	Controls (n=137) 
Lifetime cigarette consumption (x 10³) (Mean ± SD) 	122 ± 140 	0.001 	159 ± 125 
Duration of smoking history (years) 	16.9 ± 15.3 	0.01 	20.7 ± 13.1 
Average cigarettes/daywhile smoking 	12.9 ± 12.2 	<0.001	16.7 ± 10.4 


5.4 Discussion and Conclusion

In this chapter I analysed the smoking habits of cases and controls, with the results showing a significant negative association between smoking and ALD. This persisted in subgroup analysis.  

Data relate to a large number of subjects (483), both groups were matched and had detailed characterisation. They had significant and comparable alcohol intake histories which proved extremely useful as in some studies the effect of smoking cannot be characterised due to its strong association with drinking. The cases had significant liver disease with an average Child-Pugh score (CPS) of 10, indicating Child C disease. The controls had no evidence of liver disease through detailed clinical examination, blood tests and ultrasound examination. This adds to the strength of this case-control analysis. 

Smoking history was detailed as it was assessed over the lifetime, taking into account variations at different stages of life. The vast majority smoked cigarettes, other forms of smoking were excluded and it was unlikely they would have affected the results. Controls had more ex-smokers and less non-smokers which led to a significant increase in total and average  consumption during both smoking years and lifetime. 

The main limitation is that no data were available on patients’ smoking patterns and some of the recalled data went back many years, therefore the reported rates from patients’ younger years may not have been as accurate. It was easier for subjects to recall when the cigarettes came in packets (i.e. “one” or “a few”), while some subjects smoked between 40 and 60 roll-ups per day. Recalling money spent on smoking was also helpful. 

These results are interesting as the data are consistent with a protective effect of smoking against ALD in heavy drinkers. This is plausible as it has also been reported in other immune conditions (below). However, another possible explanation is that liver disease in the subject cases affected their smoking habits. This may be related to differences in the liver enzyme CYP2A6 responsible for nicotine metabolism. Patients with liver disease have been found to have reduced metabolism of nicotine, which in turn leads to greater accumulation of the product with worse side effects and hence reduced consumption. We cannot rule out other confounding environmental factors associated with smoking.

This has been an important step in assessing risk factors for ALD, especially given the limited availability of data, some of which are many years old. The advice remains on various forums to either decrease or stop smoking and to lead a healthy lifestyle, for obvious reasons, but these results are interesting and warrant further exploration in the future.






Excess alcohol intake is a risk factor for ALD, however the relationship between the two is not straightforward. Studies have suggested a dose–response relationship between alcohol ingestion and alcohol-induced liver damage  ADDIN EN.CITE [33, 34], with the risk significantly increasing above 7–13 drinks/week for women and 14–27 drinks/week for men [35]. 
The Dionysos study, a large cohort study of the prevalence of ALD in two northern Italian communities, suggested that drinking > 30 gram of ethanol/day (26 units/ week) increased the risk of developing ALD for both men and women. 

On the other hand, increasing intake above this level may not be associated with further increase in the risk of ALD or in the severity of liver injury [36]. 
A large prospective study of around 6,000 alcohol misusers in Denmark showed no significant relationship between the risk of death from cirrhosis and either the average number of drinks per days or the duration of alcohol consumption [37].  
Furthermore, it is interesting that even with a daily consumption of > 120 gm/day, the risk of liver disease was only 13.5% and that of cirrhosis 6% [58]. The risk also seemed to increase after the age of 50.

This evidence suggests that it is not fully clear whether the risk of ALD is related to rate, amount, duration or age of onset of alcohol consumption.





Information about subjects was collected as part of case-control studies analysing genetic and environmental risk factors for ALD. The period covered is 1998 to 2008. All subjects gave written consent.

Cases had to meet the inclusion criteria of excess alcohol intake > 60 units per week for men or > 40 units per week for women for at least five years until the date of decompensation. They had significant liver disease with Childs Pugh grade B or C, abnormal liver tests and ultrasound scans. All cases had a full liver screen to rule out other liver disease, as previously described. Liver biopsies were available in one-third of patients and were consistent with ALD. A total of 330 cases were included in this analysis.

Controls also had to drink at least the same amount of alcohol specified above for five years until the time of the interview. We took a number of measures to include controls with ALD. They had no clinical signs of liver disease. Blood tests showed no decompensation or other liver pathology. Ultrasound scans showed normal or fatty/bright liver. All had normal platelet counts except two (low counts can result from splenomegaly secondary to portal hypertension, which is a sign of cirrhosis). We were able to calculate a PGA index (using prothrombin time (P) serum gamma-GT(G) and apolipoprotein B1 (A)) for two-thirds of patients and it was less than 6 (a PGA value of < 6 is 90% exclusive of cirrhosis [130]). A total of 238 controls were recruited.

All subjects were asked to complete a lifetime alcohol questionnaire [156]. They recalled alcohol consumption at different stable drinking phases in their lives, such as when at college or in the army, etc. Each phase was explored as an average week documenting intake at home or outside, at weekdays and weekends. The predominant beverage group was recorded. Quantities of beverages consumed were translated into units if not already reported as such, and total consumption per week and over the lifetime summed up. We also calculated total duration and age at the start of all periods when the subject consumed >0, >40, >80, >120, >160 and >200 units alcohol/week.

All questionnaires were filled in by either the subjects or investigators (AA, JJ or MP). Sums were calculated by JJ only to avoid inter-investigator bias. 

We also obtained body weight data on 216 out of 238 controls (90%), done at the time of recruitment. As for cases, many had fluid overload, a sign of liver disease, so weight data were less available and collected retrospectively, pre-fluid retention, in 198/330 (60%).





We recruited 330 patients, 233 (71%) of whom were men. Men constituted 78% of the control cohort – 187/238. The male/female ratio was not significantly different between cohorts. Average age was also 48 years for both groups. Other demographic criteria were comparable to those reported in previous chapters.

(1)	 	Total lifetime alcohol (TLA), gender and beverages: 
































































(2)	Alcohol consumption duration, threshold and age 












































However, patients started drinking over each level at an older age than did controls (Fig. 6). The relationship between presence of ALD and age when first drank over each level (except >200 units/week) remained significant in multiple regression analyses (p=0.001-0.013). 









































In this chapter I report analysis of another important risk factor for ALD. In the first part we found no difference between cohorts regarding their average weekly alcohol intake or duration of consumption, a feature that we noted in the analysis of cohorts’ demographics in all of the previous chapters. It is interesting, however, that the controls’ TLA was actually greater than that of cases.  Furthermore, none of the alcohol beverages per se were identified as a risk factor for ALD.

The male-female patterns of beverage drinking are actually consistent with national data. The health survey of England 2012 showed that 21% of men and 13% of women had drunk more than double the daily recommended units of alcohol in the previous week. The majority of men had drunk normal-strength beer, lager, cider or shandy (62%); a third had drunk wine (33%) and just over a fifth had drunk spirits (22%). In contrast, a majority of women had drunk wine (64%); a quarter had drunk spirits (26%) and a fifth (19%) had drunk normal-strength beer, lager, cider or shandy.

The data do not, however, support increased female susceptibility to ALD given that male-female differences in alcohol consumption are found regardless of the presence or absence of liver disease, although neither do they exclude it. 
 
In the second part of the analysis we categorised consumption into thresholds. There were no differences in duration or average alcohol use.

We did, however, identify a risk factor for ALD, which is the age of starting to drink at any level (the risk is associated with starting at an older age). This observation is at least consistent with the idea that the older liver is more susceptible to development of ALD. The findings are consistent with a large Danish study in 2004. 

This is a good size study with more than 500 subjects matched for age and gender. Both groups were recruited from the same population of South Yorkshire, mainly Sheffield. As explained before, both cases and controls had to have drunk the same minimum amount of alcohol for a reasonable duration (five years) prior to recruitment. Cases had to have significant liver disease/cirrhosis and underwent an extensive liver screen to rule out any other undiagnosed liver pathology. Controls, on the other hand, had no evidence of significant liver disease. We are as confident of this as it is possible to be without having an actual liver biopsy.

The main limitation of this study is that alcohol data were mainly self-reported and spanned over several decades in certain patients. Occasionally, subjects’ partners were present and contributed to the alcohol history. We did not access or review other hospital or GP records to validate these findings. In addition, alcohol intake was for a variety of beverages of variable volumes and strengths. 

Despite these limitations, alcohol abusers’ self-reports of daily drinking were found to be highly reliable (r = 0.79–0.98), although these were over the preceding one-year period and cannot be generalised for all abusers [156].
We also explored intake at various stable phases in life and over as many years as possible using a timeline questionnaire. This quantitative method of assessing alcohol intake has been found to be much better at picking up certain types of ethanol consumption days, especially hazardous ones, and hence provides a more accurate alcohol history than other methods used in the past [131].
We also used very few investigators and only one person carried out the beverage conversions and sums. We used the same national unit conversion chart for all subjects. Even with possible variations in reporting and/or recording, the results were not significantly different between cases and controls. Gender differences were consistent with national data.

It is possible that metabolism of alcohol changes with age and therefore, the older the subject, the more susceptible he or she is to the toxic effect of alcohol, although this is yet to be proven in large studies.

I have previously shown that there is no significant familial risk of ALD, thereby prompting an assessment of potential environmental factors. In this study detailed analysis of the characteristics of alcohol consumptions identified only the age of starting to drink as a risk factor. Further study of other environmental factors like diet and drugs is crucial to understanding ALD variable susceptibility.  






We aspired to identify every patient with D-ALD in Sheffield over a specified period of time. This had not been attempted before within a specified geographical area using specific defining clinical criteria rather than patient discharge codes, such as those contained in hospital records.
We proposed identifying these cases from different sources and then overlapping them using an approach derived from Metcalf [157].  












We defined D-ALD as liver failure in a subject with previous or current history of excess alcohol intake. The subject must have had biochemical and radiological evidence. However, defining this in terms that can be applied to search criteria was not straightforward especially because this was not something that, to our knowledge, had been attempted before. When deciding the criteria, we had to consider that a search of a huge hospital database should identify as many potential cases as possible yet not generate a huge and possibly unmanageable list of subjects.

It was very useful that the Liver Unit at the RHH had a list of 249 patients with definite D-ALD who presented between 01/04/98 and 31/12/05. They were recruited into case-control studies and filled in a number of questionnaires. That cohort became the basis of my revalidation of the search criteria later on, in addition to a number of additional patients that we had also recruited by then.
 
7.2.1	Inclusion criteria from the biochemistry database and validation

All the biochemistry data for Sheffield and beyond were stored in one large database at STH. We decided to base the definition of decompensated liver disease on the Child-Pugh system/score. This is based on five criteria: three are laboratories (bilirubin, albumin, clotting) and two are clinical features (ascites and encephalopathy). CPS scores range from 5 to 15 (A: 5–6, B: 7–9, C: 10–15) (Table 1).


Table 1: Child-Pugh scores (scores range from 5 to 15)

Measure	1 point	2 points	3 points

Total bilirubin (​http:​/​​/​en.wikipedia.org​/​wiki​/​Bilirubin" \o "Bilirubin​) (μmol/l)	<34 	34–51 	>51
Serum albumin (​http:​/​​/​en.wikipedia.org​/​wiki​/​Serum_albumin" \o "Serum albumin​) (mg/l)	>35	28–35	<28
PT INR (​http:​/​​/​en.wikipedia.org​/​wiki​/​Prothrombin_time" \l "International_normalized_ratio" \o "Prothrombin time​)	<1.7	1.71–2.30	>2.30
Ascites (​http:​/​​/​en.wikipedia.org​/​wiki​/​Ascites" \o "Ascites​)	None	Mild	Moderate to Severe
Hepatic encephalopathy (​http:​/​​/​en.wikipedia.org​/​wiki​/​Hepatic_encephalopathy" \o "Hepatic encephalopathy​)	None	Grade I–II  	Grade III–IV (or refractory)

We defined decompensated liver disease as Child’s grade B or C; therefore, for inclusion, there had to be a score of 7 or above. This formed the basis of the inclusion criteria from the biochemistry data files. (Albumin and bilirubin are performed in the clinical chemistry lab on the Beckman LX20 instrument, lab measurements are explained in the appendix (Table 4).)

We intended on including every patient who had an abnormal result, i.e. albumin < 36 (low) and/or bilirubin > 33 (high). Electronically, this was complicated by the fact that the above sentence meant creating five categories based on the five possible combinations (in order for the CPS to be ≥ 7 and therefore Child’s grade B or C for each category):

Category 1 (Cat 1) - albumin > 35 and bilirubin > 51
Category 2 (Cat 2) - albumin > 35 and bilirubin < 52* (with ascites on ultrasound)
Category 3 (Cat 3) - albumin < 28 and bilirubin < 34 
Category 4 (Cat 4) - albumin > 27 and bilirubin < 34 * (with ascites on ultrasound)
Category 5 (Cat 5) - albumin < 36 and bilirubin > 33


By definition, any subject in categories 1, 3 and 5 would have a CPS of at least 7, while those in categories 2 and 4, in the absence of any other abnormality, would score 6, hence the requirement for having ascites on the ultrasound scan (Table 2).

Table 2:  Minimum scores based on the criteria 








We took this approach because we wished to develop an algorithm, based only on electronically available biochemistry and ultrasound data, which would detect all cases of D-ALD (i.e. with a CPS of 7 or more). This approach might not detect patients with a CPS of 7 or more, which was in part derived from coagulopathy (INR of >1.7) or encephalopathy. However, we had observed that coagulation testing was often not performed in patients with liver dysfunction and, furthermore, that having ALD severe enough to result in an INR of 1.7 (the level needed for an extra Child-Pugh point) was nearly always associated with bilirubin/albumin abnormalities. This would be sufficient to place the subject into one of the above categories. We speculated that the same would apply to encephalopathy, which could further only be documented by a review of clinical records and was therefore not suitable as a screening parameter. 

In order to test this approach, I applied these criteria to a sample of 275 known ALD patients (249 in the ALD file plus 26 newly recruited). Two in category 4 were found not to have an extra feature of ascites on their abdominal ultrasound, therefore, using the above criteria we anticipated identifying all but 1% of suspected ALD subjects (Table 3).









None of the above 	2	1






7.2.2	Inclusion criteria from the radiology database and validation

All patients with D-ALD should have at least one ultrasound scan of the abdomen. The scan report is always in the form of free text. No single word or combination of words is known to describe D-ALD and we had to come prepared with our own criteria. This was done through extensive assessment of ultrasound reports of known ALD patients, and although this may seem complicated, was the best way to capture as many of the cases of interest as possible.
  
I manually read the ultrasound reports of a sample of 266 already known ALD patients (249 in the ALD file plus 17 newly recruited). Given the free text nature of the reports I found a variety of key words/word combinations (below) which were present in 90.4% of all reports. They were all included to increase the sensitivity of the search. Of the reminder, eight (3%) had a normal scan, 15 had “fatty/bright liver” alone (5.6%), two had “splenomegaly” alone and one had “hepatomegaly” alone (1%). Using the criteria below we anticipated being able to identify 90% of the scans of potential ALD subjects.  

Therefore, a potential case had to meet at least one of A or B:  
A)	A scan with any of the following words: “ascit*”, “varices”, “retrograde flow”, “cirrho*”, “fibrosis”, “fibrotic”, “coarse”, “irregular”, “nodular”, “hyperecho*”, “heterog*” (the star symbol * in a search engine indicated all the possible derivative words of the one before this symbol)


B)	A scan with any of the following word combinations; 
(a)“hepatomegaly” or “enlarged liver” AND “splenomegaly” or “enlarged spleen”
(b)“bright” or “fatty” or “bright fatty” AND “hepatomegaly” or “enlarged liver” 
(c)“bright” or “fatty” or “bright fatty” AND “splenomegaly” or “enlarged spleen”

Words like “fatty” and “bright” as sole abnormalities are very common findings on ultrasound reports in general but were present in only 5.6% of all validation ALD scans and were therefore excluded as they would result in a very high number of extra scans to analyse. We also accept that some cases may have had a normal scan (3% of validation sample), not have had a scan at all or have had a key word other than those mentioned and would therefore be missed. It is also worth mentioning that there were undesirable words which were used to filter the results, as I will explain later.

Time and place:
We intended on recruiting every case with a Sheffield postcode between 1998 and 2008. Unfortunately, the Trust database did not cover this 10-year period. 
We also decided that both chemistry and ultrasound records should be within 60 days of each other. This was based on the fact that about 95% of patients in the validation reference cohort had a scan within two months of the chemistry result. Clinically it also made sense as it meant a subject was more likely to have had acute liver failure as abnormal results are not so distant from each other. 

7.2.3	Exclusion 
Subjects with a positive result for hepatitis B or C were identified through a search of the Trust’s virology database. This covered a 10-year period from 1998 to 2008. In total there were 6,286 results (some patients had more than one). Out of these, 893 (13.7%) had incomplete information (no DOB, NHS number, hospital number or an indeterminate result). The remaining 5,393 results represented 2,996 unique patients using forename/surname/DOB (f/s/d). Of these, 2,113 (70.5%) had an NHS number. 
These were added to a list of patients with autoimmune hepatitis on the department’s database (n=227). The resulting names were cross-referenced with the results of the initial search and corresponding records excluded.
 

Therefore, potential cases resulting from the above steps were included pending a review of hospital records by myself to assess whether they met the inclusion criteria. Time of onset of ALD was defined in two ways: (a) date of first recorded decompensation and (b) time (to nearest month) of onset of symptoms.  





Biochemistry and ultrasound search

(1)	To test the combined inclusion criteria, an initial validation search of all chemistry databases (by David Drew – DD) and ultrasound databases (by Pete Metheral – PM) from 1998 to 2005 was performed. This was specifically done to validate against the 249 patients with known ALD in the Sheffield ‘ALD file’. The search identified 225 out of 249 patients (90%). The remaining 24 were missed but this was expected because five had “bright/fatty liver” alone and 19 had a normal scan or no scan report was available at the time of the search.   

Then, a wider search was carried out by DD to identify all patients meeting the chemistry criteria (between January 2004 and June 2008 – four and half years). It is worth mentioning that the “ascites” criterion for categories 2 and 4 was applied here. The total result was 284,273 records. Of these, there were 56,598 records which appeared in both categories 2 and 4 and these were removed, resulting in 227,675 records relating to 15,512 unique patients. A record is a blood test at a certain time and a patient could have more than one record. When an NHS number is present this is usually unique for a patient, otherwise f/s/d were used to remove duplicate patients.












The data obtained in the search were patient’s name, hospital number, NHS number, date of birth, albumin/bilirubin result and its date. This would have been the FIRST abnormal result on the system for each subject.

(2)	The next step was to search the Trust’s main database for ultrasounds to identify all patients who met the inclusion criteria. Given the sheer number of patients we used the results of the previous clinical chemistry search as a reference population. This was done by PM for the period from January 2003 to April 2008 –four years and four months. It resulted in two lists: the first contained 7,718 scans (4,948 patients) and the other contained 374 scans (335 patients) corresponding to search criteria A and B respectively. The total was 8,092 records representing 5,037 unique patients (246 were present in both lists.) 

Therefore, the resulting file at the end of this search included patients with abnormal chemistry and ultrasound findings as per the inclusion criteria. Some patients had more than one record, i.e. more than one scan meeting the criteria or few blood results; they were included pending filtration at a later stage. 

Data obtained in addition to the patient details were the date of each scan, the actual scan report, the key words highlighted in that scan and the number of abnormal chemistry samples for that patient. 

It is worth mentioning that we were able to identify the time between each scan and the first abnormal blood result. This was important as it potentially indicated the time of the first index episode of decompensation.

Year 2004 capture analysis 

(3)	 I selected one year to attempt to explore the data and modify criteria if necessary and to use as a model for further years. The resulting file from above was further analysed as follows:

A -	I identified scans which were performed in 2004.

B - I applied the place and time criteria [only patients with a Sheffield postcode (Appendix, Table 5) and records had to be no more than 60 days from the first chemistry sample]. This was to make certain these were index episodes. It was unlikely that a scan many months apart from an abnormal blood result would indicate someone ill with liver failure and needing admission.

C - Records were initially extensively searched (electronically) to identify non-desirable/exclude key words which would indicate another liver disease or another illness and therefore prompt exclusion. These were words such as “cancer”, “carcinoma”, “malignancy”, “omental cake”, “metastasis/metastatic”, “obstruction” and “dilatation”. However, due to the free text nature we could not distinguish if a key word was mentioned with the word “no”. For example, a record could read: “no evidence of cancer”. Therefore, I manually read and labelled all the scans. 

D - This file was also cross-referenced with lists of known ALD, virology and Autoimmune Hepatitis (AIH) which were highlighted at the beginning of the chapter. 

This resulted in 1,002 records relating to 832 subjects (unique by f/s/d as not all had an NHS number). As mentioned earlier, some had more than one scan. They were classified as:

	“In” (possible ALD – no reason to exclude) 
	Already known ALD 
	“Out” (non-liver disease or liver disease other than ALD – can be excluded).

 Exactly half of the records (501) corresponding to 448 patients based on the ultrasound scan review I felt could be ALD and thus needed further exploration.  

Table 5: Classification of records from the 2004 capture file (n=1,002)
Diagnosis 	number
In - Possible ALD	501
Known ALD	120
Out - Excluded:Non chronic liver diseaseViral hepatitisCardiac failureAIHPBCNASHPSCLevine shuntHaemochromatosis	38130143131153221

 
(4)	Adding discharge data: We suspected the type of subject we were trying to identify with D-ALD was likely to be ill and require hospital admission. This was supported by the fact that only two out of the 249 (1%) patients with ALD known to the department were outpatients. 

A - All names from the ‘2004 file’ (n=832) were sent to Information Services at the Trust to identify their inpatient activity, i.e. if any had a hospital admission. This would help in two ways: the first would be knowing their discharge diagnosis and the second would be to aid in clinical note review at a later stage.  
Almost all the patients in the list (826/832 (99%)) had at least one discharge episode, totalling 15,559 episodes (with duplication) between 1/1/2000 and 30/9/2008.

B - We proposed that any inpatient activity would be within two months of a scan, i.e. 2004 ± 2 months. Therefore, I limited the previous result to the target period from 1/11/03 to 1/3/05, resulting in 4,059 discharge episodes (with duplication) for 639/832 patients (77%).  
The resulting file had hospital episodes including date of admission, date of discharge, primary diagnosis and ICD-10 code, hospital admitted to and whether the patient was currently alive or not. ( ICD-10 is the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization) 

C - I then combined this file with the ‘updated 2004 file’ and found that 273 (61%) out of the 448 patients (who were labelled as “in”) had a discharge episode within the specified period (corresponding to 313 records and 448 discharges).
It is also worth mentioning that even though the remaining 448 – 273 = 175 patients were not admitted to hospital, they fulfilled the inclusion criteria and could still have D-ALD.  

D - I reviewed the discharge diagnoses of all 273 patients and was able to exclude a further 29 patients (23 had cancer, two had PBC, three had other conditions). Almost half (46%) of the remaining 244 patients were alive at the time of analysis. Looking at the primary diagnoses and codes of these, only 18 had ALD and another 10 had non-specific cirrhosis (28/244 (11%)).

Therefore, using multiple searches and overlaps of databases, there were 244 patients from Sheffield with no known liver disease who had at least a blood test and a scan in 2004 no more than 60 days apart, thereby meeting the inclusion criteria. They were admitted to hospital with decompensated liver disease, likely ALD, until proven otherwise. 

Table 6: Number of patients captured throughout stages 

	File	Results 	Patient (n)
1	Chemistry search 	227,675 	15,512
2	Radiology search 	8,092	5,037
3	2004 - Sheffield only and 2 months’ difference	1,002 	832
4	2004 updated (Possible ALD)	501	448
5	2004 updated - possible ALD and discharge 	313	273
6	Final result after exclusions  		244









7.4 Discussion and Summary

In this chapter I have presented a novel approach to identifying patients with ALD in a defined geographical location, which has not been attempted before. Patient “capture” proved to be very difficult and complicated and was therefore not completed as intended, but the methodology and preliminary results may provide the basis for future work. Identifying all patients with ALD is important not only for this study but also has implications for public health to help measure the burden of this significant illness.

The advantage of carrying this approach out in Sheffield is the fact that the city has only one secondary care trust (STH) with two principal sites, meaning all data are stored in one location.
 From thousands of records and using the process described above and multiple filtering searches, I managed to generate a relatively small list of potential cases. Ultimately, the aim was to review these notes to assess the alcohol history, albeit with the hope of decreasing the numbers further. 

ALD has no specific definition like, for example, PBC, which has defined biochemical criteria, and this posed problems when searching databases. We relied on our own cohort of patients to identify searchable criteria and for validation. Our concern from the beginning was not to miss/exclude genuine ALD. 

The chemistry and ultrasound databases were huge, creating tens of thousands of records, often with multiple tests per subject meeting the criteria. This made cross- referencing harder, especially when using f/s/d. Not to mention some files and lists had spelling mistakes and some patients did not have an NHS number.

The ultrasound criteria were a major challenge. Reports are usually in free text and were conducted by different radiologists with inter-reporter variation. I performed an extensive word and sentence search and various validation attempts for each one (results not shown). This resulted in a detailed and reliable electronic definition to capture the majority of patients. Unfortunately, this was not possible when excluding subjects as we had to rely on the human factor (i.e. reading the scans).  

We realised that in the process of defining ALD, some potential subjects may have been excluded (normal biochemistry or fatty liver only on scan), but using validation we suspect the percentage of such patients to have been small. Also, some of the subjects excluded on the basis of having other diseases may have had ALD. We addressed this by including all records per subject, not only one, to optimise the chance of capturing those with ALD, as one scan may have contained a favourable word/sentence not present in another. 

The 2004 results were very interesting. They showed that 273 patients from Sheffield had an abnormal chemistry and ultrasound scan, were not known to have liver disease according to any of the department lists, supposedly had their first episode of decompensation in 2004 and were admitted to hospital, in addition to the 175 patients who fit the criteria but who had not been admitted to hospital. This meant that the resulting figure was much greater than anticipated.


Possible explanations include the following: firstly, cases may have originated from the NGH (the second site of the Trust) as most of the known ALD patients were from the RHH where the Liver Unit was based and cases were proactively identified over the years. Nevertheless, there were about 35 new cases at the RHH in 2004, with a similar number expected at the other site. It is not inconceivable that these were D-ALD cases which were simply either managed by other teams, discharged from accident and emergency, self-discharged or even died soon after admission. Secondly, using the category 3 chemistry criteria (very low albumin and normal bilirubin), we may have included a variety of acute illnesses that often lead to a temporary drop in albumin (these made up 4% of patients in the validation cohort). Nevertheless, their inclusion was also because of an abnormality on their scan, although this was not necessarily related to an underlying ALD. Thirdly, it is plausible that these extra patients had NAFLD. Variable prevalence of NAFLD was reported depending on the population studied and methods used to establish diagnosis, but it is estimated to be 6–35% with a median of 20% [158]. The Dionysos nutrition and liver study based on ultrasonography showed that the prevalence of NAFLD in Italian subjects with and without suspected liver disease was 25% and 20%, respectively [159].

 Unfortunately the hospital discharge data was not accurate enough to draw conclusions about the likelihood of these patients having alcoholic liver disease. Instead they were only useful as an excluding method of non -ALD.
Out of the initial group of 832 patients, 639 subjects had 4095 discharge episodes within the specified time frame with 556 unique ICD-10 codes relating to almost all discharge categories (Appendix Table 6). A detailed look at these codes showed that only 15 were “alcohol” related, 2 had “non biliary cirrhosis”, 3 had “varices” and only one was “encephalopathy”. Specifically only 19/556 had the liver related ICD code K.7* (Appendix Table 7)
Furthermore coding alone would have picked only 11% of the potential cases at the end of my analysis (28/244). Potentially this number will increase if secondary and tertiary diagnosis were available. I also looked at the coding of sample of known cases of ALD who presented in 2004 and only 6/23 (26%) had Alcoholic liver disease mentioned (appendix table 8)

The next important step is to review the notes and establish the alcohol history and possibly further modify the criteria to narrow the search results. This step was not completed as it required the requesting and physical review of hospital records comprising several hundred notes. I believe that with the expansion of electronic records nowadays, this task should be relatively easier. Also, the use of any more available databases of liver disease will further help to refine the search.











Chapter 8: Summary of Conclusions, Further Discussion 
and Future Work

This has been a large and unique case-control study and the first of its kind in Sheffield.
 I compared the characteristics of the two groups and explored potential risk factors for the serious issue of D-ALD. This is not fully understood, especially with only a minority developing ALD, and has huge medical and social implications, especially in current times. 
  
I have shown that:
- the attribution of genetic factors is modest,
- there is no relation to birthweight, 
- there is a negative effect with smoking,
in addition to developing a new guide to help identify all cases of D-ALD in a given population. 





 The number of subjects in the initial studies was expanded further, but recruitment was an issue throughout the study. It was conducted mainly by myself and my colleague JJ, a part-time research nurse working two days per week. We managed to recruit a further 143 cases and 86 controls. Four controls were excluded after recruitment (three had abnormal ultrasound and blood tests and one was found to have had an HCV positive result in the past).

We intended to recruit more patients but this presented a number of difficulties. On average, out of each four subjects reviewed for potential cases/controls, only one was included. A sample of 124 potential subjects with heavy alcohol intake at three sites (RHH, NGH, Nether Edge Hospital) who were not recruited is analysed. Reasons for non-inclusion are shown in Table 1. This was disappointing and time-consuming as assessing suitability often involved reviewing all available results and letters and sometimes included a short face to face encounter. 

 
Table 1: Analysis of non-inclusion causes of 124 potential subjects

Category	Description	Number
1	Admitted but died before recruitment	6
2	Alb/Bili or alcohol not fitting - but may fit later as case	57
3	had previous decompensation but not known when/where	2
4	Refused	0
5	Not done /missed/ discharged 	34
6	Made contact /given info but not recruited 	1
7	Viral hepatitis	11
8	Other liver disease or cancer	6





Also, the number of new controls recruited was much lower than cases. It was often the case that we would identify a potential control yet when reviewing previous chemistry results, even a single abnormal one would lead to exclusion. The most common example was low serum albumin, which can be caused by various conditions, including nephrotic syndrome, heart failure, malnutrition and acute and chronic inflammatory responses. Unless we could identify evidence of such conditions at the time, such as infection (for example, a positive culture or abnormal chest x-ray) or pancreatitis (inflammation of the pancreas due to excess alcohol), then that subject could not be included as the possibility of an underlying chronic liver disease could not be ruled out. This was mainly amplified by the fact that we had access to all chemistry results anywhere in Sheffield. Another explanation is that controls had to be health care seeking, which ruled out other sources used in previous studies like pubs or adverts on local radio or in newspapers, etc. 

Participation of different specialities was lower than expected. All general practitioners and consultants were sent an email early on about the study, but very few replied. We also explored alcohol services in Sheffield and whilst we recruited some patients  from dry houses, the turnover in general was low as the subjects would spend months at a time in these places. On the other hand, the Sheffield Alcohol Advisory Service (SAAS) had a higher turnover, yet the nature of their drop-in sessions made it difficult to arrange further meetings with interested subjects. On occasion, these potential subjects would decline coming to hospital to have blood tests or a scan. We realised that the only way would be to review more patients and further engage with our colleagues across the Trust. We put out a simplified flyer for the study in many locations and asked junior doctors to keep a list of any potential subjects, especially controls, for us to review later.

Once a suitable subject was identified, the actual recruitment process was lengthy, given the number of questionnaires to be completed. At times this was carried out at home, and there were also delays as a result of obtaining the questionnaires through the post.  


8.2 Cases and Controls 

 The patients and controls in this study represent two large, well-defined cohorts with widely differing susceptibility to development of ALD. The patients were unselected cases of D-ALD, nearly all requiring admission to hospital, and many with ascites and coagulopathy. Although liver histology was available in only 32% of patients, other liver diseases were adequately excluded by detailed non-invasive screening. We believe that decompensation is a more clinically important index of disease severity than cirrhosis on biopsy. Prognostic indices for ALD use clinical and biochemical indices and none use histological features. Most cases (70%) had either biopsy-proven cirrhosis or clinical or ultrasound evidence of portal hypertension, which has been presumed to indicate cirrhosis [65].  

The HD controls (who did not undergo liver biopsy) are likely to have had fatty liver infiltration, seen in most heavy drinkers, but did not have decompensation and are unlikely to have had cirrhosis. The a priori likelihood of a heavy drinker developing cirrhosis is less than 10% [58], a probability lowered still further by the normal clinical, laboratory and ultrasound evaluation. However, we could not exclude milder degrees of fibrosis in the controls. Because recruitment of HD controls was limited by the need to formally exclude liver disease, we sought these subjects from several sources and without any other selection criteria. They were, however, recruited prospectively over the same time period and from the same eligible population. Indeed, we have no systematic reason to suppose that had one of these controls developed D-ALD over the study period, they would not have been one of the cases. Although the controls were slightly older than the cases, the two cohorts were not significantly different with regard to gender ratio or lifetime alcohol consumption.
 8.3 Future Work 

The aspect of environmental factors has huge potential and, we believe, provides a basis for future analysis. During the course of this project we acquired a significant amount of information about other factors like social deprivation (early life and current), prescribed medications from general practice and diet through food frequency questionnaires.  
Diet data were not analysed as they were only provided by small numbers in each group (less than 100); diet does, however, remain a potentially significant factor. 
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Table 1: breakdown of ultrasound finding for cases (excluding normal and fatty liver)















































Table 2: Patients with decompensated ALD: details of liver disease in relatives
ID	Subject	Relative	Q. alcohol	Q LD	Phone/clinic Follow-up	Known to us	Evidence	Conclusion
1	MG	Brother	Heavy	yes	yes	No	 “A bit of liver damage”	Poss. ALD
2	RM	Brother	Heavy	yes	yes	No	Liver disease	Poss. ALD
3	CB	Brother	Heavy	yes	no	No	“Possible liver disease”	Poss. ALD

















17	CE	Mother	Heavy	yes	yes	No	“liver shunt for GI bleed”	ALD
18	NG	Mother	Heavy	yes	OPC	No	“jaundice, abdominal swelling, liver failure”	ALD
19*	LF	 Mother 	social	no	no	Yes	jaundice, ascites, heavy drinker	ALD
20*	SH	 Brother 	-	-	-	Yes	jaundice, ascites, heavy drinker	ALD
21	AM	Mother	?	yes	no	No	“liver cysts”	Not ALD





27	KN	Brother	Heavy	yes	yes (mother/sister)	No	Mother/sister not aware of liver disease	No LD
28	SQ	Father	Heavy	yes	Yes (mother)	No	“no liver problems”	No LD
29	MC	Mother	Heavy	yes	Yes (sister)	No	“alcohol-related angina only”	No LD
30	AM	Brother	Heavy	yes	OPC	NO	No liver problems	No LD





Table 3: Heavy drinking controls: details of liver disease in relatives
ID	Subject	Relative	Q. alcohol	Q LD	Phone/clinic Follow-up	Known to us	Evidence	conclusion
1	JW	Brother	Heavy	Yes	yes	No	“probable liver disease”	Poss. ALD
2	JT	Father	Heavy	Yes	yes	No	“possible cirrhosis”	Poss. ALD
		Sister	Heavy	Yes	yes	No	“liver infection”	Poss. ALD





7	RM	Sister	Heavy	Yes	yes	No	jaundice, “some liver damage”	ALD
8	GG	Father	Heavy	Yes	no	No	“cirrhosis”	ALD
9	AL	Brother	Heavy	Yes	yes	yes	“jaundice, ascites, GI bleed, cirrhosis”	ALD
10	MH	Brother	Heavy	Yes	yes	No	ascites, “2% of liver left”	ALD
11	AB	Mother	Heavy	Yes	yes	yes	jaundice, ascites, “Doctors said cirrhosis”	ALD
12	PD	Brother	Heavy	Yes	Outpatient	No	jaundice	ALD
13	MB	Mother	Heavy	Yes	In person	No	Cirrhosis, “died age 62”	ALD
14	JF	Mother	Moderate	Yes	yes	No	PBC	Not ALD
15	AW	Mother	Light	Yes	no	No	PBC	Not ALD
























Table 4: Albumin and bilirubin lab test details 

Test	Lab Specification 
Albumin	Colorimetry BCP, System determines albumin concentration by means of a biochromatic digital endpoint methodology using bromocresol purple (BCP) reagent.
Bilirubin	Jendrassik-Grof method (timed endpoint Diazo method). In the reaction, the bilirubin reacts with diazo reagent in the presence of caffeine, benzoate and acetate as accelerators to form azobilirubin.


Table 5: Sheffield postcodes 




























Table 6: Summery of ICD-10 codes for all 2004 cases admitted in the target period 
	
ICD-10 version 2010	n
I Certain infectious and parasitic diseases  	23
II Neoplasms  	81
III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism  	17
IV Endocrine, nutritional and metabolic diseases  	19
V Mental and behavioural disorders  	10
VI Diseases of the nervous system  	13
VII Diseases of the eye and adnexa  	5
VIII Diseases of the ear and mastoid process  	1
IX Diseases of the circulatory system  	59
X Diseases of the respiratory system  	24
XI Diseases of the digestive system  	106
XII Diseases of the skin and subcutaneous tissue  	9
XIII Diseases of the musculoskeletal system and connective tissue  	31
XIV Diseases of the genitourinary system  	30
XV Pregnancy, childbirth and the puerperium  	8
XVI Certain conditions originating in the perinatal period  	0
XVII Congenital malformations, deformations and chromosomal abnormalities  	1
XVIII Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified  	43
XIX Injury, poisoning and certain other consequences of external causes  	62
XX External causes of morbidity and mortality  	0
XXI Factors influencing health status and contact with health services  	14
































alcoholIC cirrhosis OF LIVER	K703
alcoholIC HEPATIC FAILURE	K704
alcoholIC LIVER DISEASE, UNSPECIFIED	K709
TOXIC LIVER DISEASE WITH ACUTE HEPATITIS	K712
ACUTE AND SUBACUTE HEPATIC FAILURE	K720
HEPATIC FAILURE, UNSPECIFIED	K729
CHRONIC ACTIVE HEPATITIS, NOT ELSEWHERE CLASSIFIED	K732
PRIMARY BILIARY cirrhosis	K743
BILIARY cirrhosis, UNSPECIFIED	K745
OTHER AND UNSPECIFIED cirrhosis OF LIVER	K746
ABSCESS OF LIVER	K750
GRANULOMATOUS HEPATITIS, NOT ELSEWHERE CLASSIFIED	K753
INFLAMMATORY LIVER DISEASE, UNSPECIFIED	K759
FATTY (CHANGE OF) LIVER, NOT ELSEWHERE CLASSIFIED	K760
HEPATORENAL SYNDROME	K767


































Table 8: Primary hospital coding of patients with known ALD presenting in 2004 (n=23)

No 	primary diagnosis 	code
1	ALCOHOLIC CIRRHOSIS OF LIVER	K703
2	ALCOHOLIC HEPATITIS	K701
3	ALCOHOLIC LIVER DISEASE, UNSPECIFIED	K709
4	ALCOHOLIC LIVER DISEASE, UNSPECIFIED	K709
5	ALCOHOLIC LIVER DISEASE, UNSPECIFIED	K709
6	ALCOHOLIC LIVER DISEASE, UNSPECIFIED	K709
7	ASCITES	R18X
8	BENIGN NEOPLASM OF SIGMOID COLON	D125
9	DISEASE OF OESOPHAGUS, UNSPECIFIED	K229




14	HAEMORRHAGE OF ANUS AND RECTUM	K625
15	LIVER DISEASE, UNSPECIFIED	K769
16	OPEN WOUND OF SCALP	S010
17	OTHER AND UNSPECIFIED ABDOMINAL PAIN	R104
18	OTHER SPECIFIED DISORDERS OF BRAIN	G938
19	OTHER SPONTANEOUS PNEUMOTHORAX	J931
20	PAIN IN LIMB-ANKLE/FOOT	M7967








































































2004 possible ALD and discharge n=273
After exclusions   n=244
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